Subject Index

Abuse. See Physical and sexual abuse; Substance use disorders
Acalculias, 715
Acceptance and commitment therapy (ACT), 312, 372, 373
Acculturation, 132, 133–135
Actigraphy, 526, 530
Alcohol use disorders (Continued)
course and prognosis of, 658–659
depressive disorders comorbidity with, 263–264, 645, 650
description of, 641–643
diagnosis and assessment impacted by, 67–70
diagnostic considerations for, 644–646
dimensional vs. categorical classification of, 11–14, 39–40
environmental risk factors for, 394, 652, 653–654, 655–656
epidemiology of, 646–647
etiological considerations for, 653–658, 728–729
gender influences and differences in, 646, 647, 654, 657–658, 659
learning and modeling of, 655–656
life functioning with, 646, 660
motivational interventions for, 644, 648, 659, 661
neurobiological function in, 651, 654–655, 728
neurocognitive disorders and, 718, 721, 728–729, 731–732
operant conditioning of, 655
other substance use comorbidity with, 645, 683
personality disorder comorbidity with, 645, 650, 760–761
physical illnesses associated with, 63, 646, 653
psychological and biological assessments of, 648–653
psychopathology research impacted by, 69–71
racial, ethnic and cultural factors in, 134, 154, 643, 647, 657–658
secondary psychiatric disorder models on, 79
secondary substance abuse models on, 77
self-monitoring of, 649
service utilization impacted by, 60–61
severity rating of, 642, 644, 646, 647, 648–649, 661
suicide/suicide ideation association with, 60
trauma- and stress-related disorder comorbidity with, 391, 656
treatments and interventions for, 642, 643, 644, 645, 646, 648, 659, 661
treatments and interventions impacted by, 59, 60–61, 66
violence associated with, 59–60, 646, 660
withdrawal symptoms with, 645–646
Alexias, 714–715, 716
Amenorrhea, 474
American Academy of Pediatrics (AAP), 497
American Academy of Sleep Medicine, 525
American Foundation for Urologic Diseases, 548
American Medical Association (AMA), 642
American Psychiatric Association (APA):
 DSM by (see Diagnostic and Statistical Manual of Mental Disorders)
et eating disorder treatment guidelines, 497, 498
American Psychological Association, 648
Amnesia:
alcoholic Korsakoff’s syndrome as, 718, 729, 732
anterograde vs. retrograde, 718
dissociative amnesia as, 407, 409, 410–413, 420, 421, 431–432
as neurocognitive disorders, 717–719, 729, 732, 733
posttraumatic, 733
temporal lobe amnesia as, 718–719
Amok, as culture-bound syndrome, 412
Androgen deficiency in the aging male (ADAM), 558, 559
Aneurysms, 725, 726, 733
Anger and hostility. See also Conduct or disruptive behavior disorders; Violence dissociative disorder comorbidity with, 423
heritability of, 750
personality disorder comorbidity with, 750, 751
schizophrenia comorbidity with, 168
Animal fears:
 racial, ethnic and cultural factors impacting, 143, 144
specific phobias as, 304, 309, 326
Anorexia nervosa (AN):
 atypical, 475
clinical picture of, 473–474
cognitive functioning with, 494–496
course and prognosis of, 497–498
description of, 473
diagnostic considerations for, 475–476
dual diagnosis including, 50
epidemiology of, 477
etiological considerations for, 484, 486, 487, 488, 489, 490, 494–496
genetic risk factors for, 484
neurobiological function with, 486, 487, 488, 489, 490, 495
psychological and biological assessments of, 478–481
racial, ethnic and cultural factors in, 143, 144, 496–497
substance use comorbidity with, 50
treatments and interventions for, 497–498
Antisocial personality disorders:
case study of, 761–762
clinical picture of, 748
common factors model on, 73
dimensional vs. categorical classification of, 16
Anxiety disorders. See also Trauma- and stress-related disorders
acceptance and commitment therapy for, 312
age influences and differences in, 48, 307, 308, 309, 326
agoraphobia, 49–50, 114, 300–301, 306, 314, 323
behavioral assessments/ consideration with, 317–318, 323–326
bidirectional model on, 79–80
biological assessments/ considerations with, 318, 319–322
bipolar disorder comorbidity with, 231
classical conditioning of, 323–324
cognitive-behavioral therapy for, 311–314
cognitive functioning with, 302–303, 326–329
combined treatments for, 313–314
costs of, 299
course and prognosis of, 307, 308, 309, 310
depression comorbidity with, 6, 265, 307–308, 309, 314–315
description of, 300–306
diagnostic considerations for, 305–306
dimensional vs. categorical classification of, 4, 5, 6–7, 15–16, 305
dual diagnosis including, 41, 42, 50–51, 53, 69, 70, 73
epidemiology of, 749–750
etiological considerations for, 750, 751
gender dysphoria comorbidity with, 610
psychological assessments of, 757
structured and semistructured interviews on, 117
substance use comorbidity with, 41, 42, 50–51, 53, 69, 70, 73, 645, 676
trauma- and stress-related disorder comorbidity with, 51
Anxiety disorders. See also
Trauma- and stress-related disorders
acceptance and commitment therapy for, 312
age influences and differences in, 48, 307, 308, 309, 326
agoraphobia, 49–50, 114, 300–301, 306, 314, 323
behavioral assessments/ consideration with, 317–318, 323–326
bidirectional model on, 79–80
biological assessments/ considerations with, 318, 319–322
bipolar disorder comorbidity with, 231
classical conditioning of, 323–324
cognitive-behavioral therapy for, 311–314
cognitive functioning with, 302–303, 326–329
combined treatments for, 313–314
costs of, 299
course and prognosis of, 307, 308, 309, 310
depression comorbidity with, 6, 265, 307–308, 309, 314–315
description of, 300–306
diagnostic considerations for, 305–306
dimensional vs. categorical classification of, 4, 5, 6–7, 15–16, 305
dual diagnosis including, 42, 44, 47, 48, 49–50, 51, 53, 55, 79–80
environmental risk factors for, 329–331
epidemiology of, 306–310
etiological considerations for, 318–331
exposure therapy for, 311–312, 314
eye movement desensitization and reprocessing for, 313
feeding and eating disorders comorbidity with, 476, 497
gambling disorder comorbidity with, 48
gender dysphoria comorbidity with, 613
sexual dysfunctions and paraphilic disorders comorbidity with, 458, 463
trauma- and stress-related disorder comorbidity with, 391
treatments and interventions for, 15, 310–315
viscous conditioning of, 325
Appraisal Disruption Model, 656–657
Assessment tools. See Diagnostic and assessment tools
Ataque de nervios, as culture-bound syndrome, 330
Attentional Allocation
Model, 656–657
Attention deficit/hyperactivity disorder (ADHD):
bipolar disorder relationship to, 231–232
diagnostic and assessment tools addressing, 120
hoarding disorder comorbidity with, 359
racial, ethnic and cultural factors in, 143
Australian National Survey of Mental Health and Well-Being, 9, 10
Autism spectrum disorder, 7
Autogynephilia, 574, 608, 612, 624
Autotopognosia, 715
Avoidant personality disorders:
clinical picture of, 748
dimensional vs. categorical classification of, 15–16
dual diagnosis including, 53
epidemiology of, 749, 750
etiological considerations for, 750, 751, 752
gender dysphoria comorbidity with, 611
psychological assessments of, 757
social anxiety disorder overlap with, 303–304
substance use comorbidity with, 53
symptom overlap with, 303–304, 414
Avoidant/restrictive food intake disorder, 473
Behavioral family therapy, 189
Bereavement and grief, 11, 38, 262–263, 264–265
Berkeron’s fallacy, 36
Binge-eating disorder (BED):
clinical picture of, 474–475
description of, 473
diagnostic considerations for, 476–477
dual diagnosis including, 50
environmental risk factors for, 491–492
epidemiology of, 477
etiological considerations for, 485–486, 487, 488, 489, 491–492
genetic risk factors for, 485–486
neurobiological function with, 487, 488, 489
psychological and biological assessments of, 478–481
rational, ethnic and cultural factors in, 496–497
substance use comorbidity with, 50
treatments and interventions for, 499
Biological assessments:
for anxiety disorders, 318
for depressive disorders, 269
for feeding and eating disorders, 480–481
for gender dysphoria, 614
for neurocognitive disorders, 721–722
for schizophrenia, 180–181
for sexual dysfunctions and paraphilic disorders, 556–557, 580–581
for sleep disorders, 530
for somatic symptom and related disorders, 459
for substance use disorders, 649, 651, 652–653, 681–682
for trauma- and stress-related disorders, 393
Bipolar disorder:
age influences and differences in, 219–220, 229–231
anxiety comorbidity with, 231
attention deficit/hyperactivity disorder relationship to, 231–232
bipolar spectrum, 228–229
case study of, 235–236
child and adolescent diagnosis of, 229–231
clinical picture of, 221–222
cognitive-behavioral therapy for, 226, 227
cognitive functioning with, 56, 57, 223–224
course and prognosis of, 222–228
description of, 217–219
diagnostic assessment methods for, 232
diagnostic considerations for, 228–232
dimensional vs. categorical classification of, 4, 6, 228–229
dual diagnosis including, 41, 42, 45, 47, 48–49, 51, 52, 54–55, 56, 57, 59–60, 61, 67, 73, 231–232
eating disorder comorbidity with, 51
environmental risk factors for, 223–224
epidemiology of, 219–220
etiological considerations for, 232–234
family-focused therapy for, 226, 227, 228
future study of, 237–238
gender dysphoria comorbidity with, 610
gender influences and differences in, 220
genetic risk factors for, 73, 232–233, 234
goal dysregulation in, 224–225
interpersonal and social rhythm therapy for, 226, 227
life functioning with, 221–222
neurobiological function in, 233–235, 431
overview of, 217, 237–238
pharmacologic interventions for, 59, 220, 225–226, 236
psychoeducation for, 226–227
racial, ethnic and cultural factors in, 134, 220
schizophrenia comorbidity with, 173
service utilization with, 61
sleep disorder comorbidity with, 225
structured and semistructured interviews on, 232
substance use comorbidity with, 41, 42, 45, 47, 48–49, 51, 52, 54–55, 56, 57, 59–60, 61, 67, 73, 231
subtypes of, 218–219
suicide/suicide ideation
comorbidity with, 60, 220, 221, 236
symptom overlap with, 67, 173, 431, 610
Systematic Treatment
Enhancement Program for Bipolar Disorder, 220, 227
trauma- and stress-related disorder comorbidity with, 231
treatments and interventions for, 59, 220, 225–228, 236, 237–238
Blood analysis, 682
Body dysmorphic disorder (BDD):
case study of, 373
clinical features of, 357
cognitive functioning with, 368–369
course and prognosis of, 371–372
description of, 355–356
diagnostic considerations for, 358–359
dimensional vs. categorical classification of, 7
environmental risk factors for, 362–363, 367
epidemiology of, 359–360
etiological considerations for, 362–363, 364–365, 367, 368–369, 370
gender influences and differences in, 370
genetic risk factors for, 362–363
neurobiological function with, 364–365, 368
psychological and biological assessments of, 361
racial, ethnic and cultural factors in, 370
suicide/suicide ideation comorbidity with, 357, 371
symptom overlap with, 610
treatments and interventions for, 372

Borderline personality disorders:
case study of, 761–762
clinical picture of, 748
common factors model on, 73
course and prognosis of, 753
depressive disorder comorbidity with, 253, 265
dialectical behavior therapy for, 753
dimensional vs. categorical classification of, 16
dissociative disorder comorbidity with, 415, 430
dual diagnosis including, 47, 50, 53, 73
epidemiology of, 749
etiological considerations for, 750, 751
gender dysphoria comorbidity with, 611
mentalization-based therapy for, 753
personality dynamics in, 742
pharmacologic interventions for, 753
psychological assessments of, 757
schema-focused therapy for, 753
separation of personality pathology and, 745
substance use comorbidity with, 47, 50, 53, 73, 645, 676
symptom overlap with, 414, 610
transference-focused therapy for, 753
treatments and interventions for, 753
Brain function. See Cognitive functioning; Neurobiological function
Breath analyzer, 653
Breathing-related sleep disorders, 523, 529, 530, 531, 542
Brief cognitive-behavioral therapy, 398
Broca’s aphasia, 708, 709–710, 714, 715
Bulimia nervosa (BN):
clinical picture of, 474
cognitive functioning with, 494
description of, 473
diagnostic considerations for, 476
dual diagnosis including, 50, 52
environmental risk factors for, 491
epidemiology of, 477
etiological considerations for, 484–485, 487, 488, 489, 490, 491, 494
genetic risk factors for, 484–485
neurobiological function with, 487, 488, 489, 490
psychological and biological assessments of, 478–481
racial, ethnic and cultural factors in, 496–497
substance use comorbidity with, 50, 52
treatments and interventions for, 498–499
Case study:
of bipolar disorder, 235–236
of depressive disorders, 282–285
of dissociative disorders, 422–423
of feeding and eating disorders, 50, 52
of gender dysphoria, 625–627
of obsessive-compulsive disorders, 373–374
of personality disorders, 760–763
of schizophrenia, 193–195
of sexual dysfunctions and paraphilic disorders, 568, 584–585
of sleep disorders, 540–542
of somatic symptom and related disorders, 463–465
of substance use disorders, 659–661, 691–692
of trauma- and stress-related disorders, 399–400
Cataplexy, 528, 536, 537
Catatonia, 255, 260
Centers for Disease Control, 474
Child abuse. See Physical and sexual abuse
Chinese Classification of Mental Disorders, 142–143
Chronic fatigue syndrome, 143
Circadian rhythm sleep-wake disorders, 523, 529, 530, 531–532
Clinical considerations:
- bipolar disorder, clinical picture of, 221–222
- clinical impacts of dual diagnosis, 54–66
- clinical practice use of structured and semistructured interviews, 105
- clinical studies of dual diagnosis, 36, 48–54
- clinical training use of structured and semistructured interviews, 106, 108
- clinical utility of diagnosis, 21, 22–23, 105, 140–141, 739–740, 759–760
- depressive disorders, clinical picture of, 260–262
- feeding and eating disorders, clinical picture of, 473–475
- gender dysphoria, clinical picture of, 605–609
- neurocognitive disorder clinical presentation, 707–713
- obsessive-compulsive disorders, clinical features of, 356–358
- personality disorders, clinical picture of, 748–749
- schizophrenia, clinical picture of, 166–170
- sexual dysfunctions and paraphilic disorders, clinical picture of, 549–552, 569–575
- somatic symptom and related disorders, clinical picture of, 452–456
- substance use disorders, clinical picture of, 643, 673–675
- trauma- and stress-related disorders, clinical features of, 390–391

Cognitive-behavioral therapy (CBT):
- for anxiety disorders, 311–314
- for bipolar disorder, 226, 227
- brief CBT as, 398
- for dissociative disorders, 423, 435
- for feeding and eating disorders, 498, 499
- for obsessive-compulsive disorders, 371–373
- for sexual dysfunctions and paraphilic disorders, 562–563, 564, 566–567, 585
- for sleep disorders, 530
- for somatic symptom and related disorders, 463
- for trauma- and stress-related disorders, 396, 397–398

Cognitive functioning.
- See also Neurobiological function
- anxiety disorders and, 302–303, 326–329
- bipolar disorder impacting, 56, 57, 223–224
- depressive disorders impacting, 261, 278
- dissociative disorders impacting, 705–734
- obsessive-compulsive disorders and, 367–368
- personality disorders and, 751–752
- psychoses and, 58
- schizophrenia impacting, 56, 57–58, 166, 177, 185–186
- sexual dysfunctions and paraphilic disorders and, 583
- somatic symptom and related disorders and, 462
- substance use disorders and, 56–58, 651, 656–657, 687–688
- trauma- and stress-related disorders and, 388, 396

Cognitive Processing Therapy (CPT), 396, 397
- Cognitive restructuring:
  - for anxiety disorders, 311–312
- Cognitive Processing Therapy (CPT) as, 396, 397
- for dissociative disorders, 423
- for obsessive-compulsive disorders, 372
- for trauma- and stress-related disorders, 396, 397–398

Coital alignment technique (CAT), 566
- Collaborative Longitudinal Personality Disorders Study, 121, 752
- Collaborative Study on the Genetics of Alcoholism, 68
- Common factors model, 72–74
- Community functioning, schizophrenia impacting, 179
- Community Tracking Study, 62
- Comorbidity:
  - of attention deficit/hyperactivity disorder, 231, 359
  - complexity of, 44–45
  - of conduct or disruptive behavior disorders, 73, 74
  - co-occurrence vs., 6
  - dimensional vs. categorical classification, 6
  - of gambling disorders, 40, 48
  - of impulse-control disorders, 358
  - of neurocognitive disorders, 705, 713–720, 725
of obsessive compulsive disorders, 42, 47, 50, 53, 231, 265, 357, 358-359, 371, 373
of personality disorders, 41, 42, 47, 48, 50-51, 53, 55, 66, 69, 70, 73, 253, 265, 358-359, 391, 415, 430, 458, 463, 476, 610, 611, 645, 650, 676, 739, 748, 760-761
of physical illnesses, 463, 480-481, 497, 498-499, 529, 531, 538, 539, 549, 554, 558, 560, 646
of psychoses, 45, 48, 58, 259-260, 610, 613
of schizoaffective disorder, 416
of schizophrenia, 36, 42, 46, 48-49, 51-52, 54, 55, 56, 57-58, 39-60, 63, 64, 67, 73, 75, 76-77, 77-78, 167-170, 171-175, 185, 265, 416, 610, 645, 676
of sexual dysfunctions and paraphilic disorders, 416, 549, 554, 558-560, 566, 574, 576, 605, 608, 609, 610, 612-613, 615, 624
of sleep disorders, 225, 388, 416, 433-434, 436, 523, 527, 528-530, 531, 533, 534-536, 537, 538, 539, 590-592
of somatic symptom and related disorders, 261, 456-457, 458, 463
Complete androgen insensitivity syndrome, 606
Concussions, 705-706, 723, 724
Conduct or disruptive behavior disorders, 16, 73, 74, 120, 748. See also Anger and hostility; Disruptive mood dysregulation disorder; Impulse-control disorders
Congenital adrenal hyperplasia (CAH), 606
Conversion disorder, 451, 454, 458, 461
Depressive disorders (Continued) 

environmental risk factors for, 259, 268–269, 279–280 
epidemiology of, 265–269 
etiological considerations for, 274–281 
feeding and eating disorders comorbidity with, 476, 497 
gambling disorder comorbidity with, 48 
gender dysphoria comorbidity with, 605, 626–627 
gender influences and differences in, 266–267, 280–281 
genetic risk factors for, 72–73, 274–276, 319 
grief and bereavement relationship to, 11, 38, 262–263, 264–265 
learning and modeling of, 277–279 
life functioning with, 261–262 
major depressive disorder, 254, 255–256, 282–283 
neuroasthenia similarity to, 143 
neurobiological function in, 276–277, 719–720 
obsessive-compulsive disorder comorbidity with, 358–359 
other specified or unspecified depressive disorders, 254, 258–259, 284–285 
peripartum depressive disorders, 260 
persistent depressive disorder, 7–9, 254, 256, 281–282, 283–284 
personality disorder comorbidity with, 253, 265 
pharmacologic interventions for, 11 
physical illness relationship to, 258, 263 
positive psychology for, 262 
prenatal dysphoric disorders, 257 
pseudodementia as late life depression, 719–720 
psychological and biological assessment of, 269–274 
psychotic features of, 259–260 
racial, ethnic and cultural factors in, 133, 134, 137, 143, 152–153, 263, 267–268, 271, 280 
schizoaffective disorder relationship to, 173–174 
schizophrenia comorbidity with, 167–168, 173, 265 
screening instruments for, 269–272 
secondary psychiatric disorder models on, 79 
service utilization with, 60–61 
social functioning impacted by, 261 
somatic symptom comorbidity with, 261, 458, 463 
special settings impacting, 268–269 
structured and semistructured interviews on, 112, 113, 114, 117–118, 119, 269, 272–274 
substance/medication-induced depressive disorder, 68–69, 79, 257, 264 
subthreshold major depression, 10–11 
suicide/suicide ideation comorbidity with, 60, 253 
taxometric analyses of, 9–10 
trauma- and stress-related disorder comorbidity with, 391 
treatments and interventions for, 11, 60–61, 253, 262, 282 
Diabetes, 81, 262, 263, 270, 272, 481, 499, 531, 558, 564, 690, 726, 732 
Diagnosis and assessment. See also specific topics below for additional detail 
age influences and differences in, 47–48, 109–110 
family disorders diagnostic considerations, 305–306 
asessment tools for (see Diagnostic and assessment tools) behavioral assessments, 317–318, 360–361 
bipolar disorder diagnostic considerations, 228–232 
clinical training in, 106, 108 
clinical utility of, 21, 22–23, 105, 140–141, 739–740, 759–760 
depressive disorders diagnostic considerations and specifiers, 259–260, 262–265 
diagnostic boundaries, 5–20 
dimensional vs. categorical classification in, 3–24, 228–229, 305, 390, 451–452, 758 
dissociative disorders diagnostic considerations, 412–414, 415–416, 436 
dual, 35–81, 231–232, 264, 456–457, 610–612, 645 (see also Comorbidity) 
dual disorders impacting, 66–70, 456–457 
factor pattern investigations for, 139–140 
family assessments, 179–180 
feeding and eating disorders diagnostic considerations, 475–477 
gender dysphoria diagnostic considerations, 609–612 
item response theory (IRT) methodology of, 13–14, 39–40 
neurocognitive disorder diagnostic considerations, 706–707 
obsessive-compulsive disorder diagnostic considerations, 358–359
personality disorder diagnostic considerations, 745–747
psychopathology research reliance on, 69–70, 107
racial, ethnic and cultural factors impacting, 125–126, 132, 134, 137–147, 150–151, 152–154, 271
reference tools for (see Diagnostic and Statistical Manual of Mental Disorders; International Classification of Diseases)
reliability of, 106–107, 126
Research Domain Criteria (RDoC) for, 23
schizophrenia diagnostic considerations, 170–175
sexual dysfunction and paraphilic disorder diagnostic considerations, 549, 553, 575–576
sleep disorder diagnostic considerations, 528–530, 534–536
somatic symptom and related disorders diagnostic considerations, 456–457
structured equation modeling in, 139
substance use disorder diagnostic considerations, 644–646, 675–676
symptom expression and, 134, 141–147
trauma- and stress-related disorders diagnostic considerations, 391, 399, 400
treatments and interventions based on, 22–23, 107, 648, 677

Diagnostic and assessment tools:
Acute Stress Disorder Interview (ASDI), 393
Acute Stress Disorder Scale (ASDS), 393
Addiction Potential Scale (APS), 678
Addiction Severity Index (ASI), 679–680, 681, 691
Addiction Severity Inventory, 172
Adolescent Dissociative Experiences Scale (A-DES), 420
Agoraphobic Cognitions Questionnaire (ACQ), 316
Albany Panic and Phobia Questionnaire (APPQ), 141
Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), 679
Alcohol Dependence Scale (ADS), 650, 660
Alcohol Use Disorders Identification Test (AUDIT), 60, 650, 678
Anorexia Nervosa Inventory for Self-Rating (ANIS), 480
Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5), 115
Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV), 111, 112, 113–115, 315–316, 360, 393
Anxiety Disorders Interview Schedule for DSM-IV-Lifetime (ADIS-IV-L), 315–316
Anxiety Sensitivity Index (ASI), 460, 465
Anxiety Sensitivity Index-3 (ASI-3), 316
BDD Examination (BDDE), 361
Beck Anxiety Inventory (BAI), 140, 460, 465, 650
Beck Depression Inventory (BDI), 10, 270, 650
Beck Depression Inventory-II, 460, 465
Beck Depression Inventory-Primary Care (BDI-PC), 271
Beck Suicidality Scale, 60
behavioral avoidance tests (BATs), 360–361
Binge Eating Scale (BES), 480
blood analysis, 682
breath analyzer, 653
Brief Fear of Negative Evaluation Scale (BFNES), 316
Brief Psychiatric Rating Scale (BPRS), 177
Brief Situational Confidence Questionnaire (BSCQ), 651
Brixton Task, 494–495
CAGE, 678
Camberwell Family Interview, 179
Cambridge Depersonalization Scale (CDS), 413, 421–422
Cambridge Neuro-psychological Tests Automated Battery (CANTAB), 494
CatBat Task, 494–495
Center for Epidemiological Studies-Depression Scale (CES-D), 270
Clarke Sexual History Questionnaire for Males, 579
Clinician Administered Dissociation State Scale (CADSS), 418
Clinician-Administered PTSD Scale (CAPS), 392
Cultural Formulation Interview (CFI), 125–126
Dartmouth Assessment of Lifestyle Instrument (DALI), 172
Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV), 111, 112, 120–121
Diagnostic Interview Schedule (DIS), 459, 478
Diagnostic Interview Schedule for DSM-IV (DIS-IV), 111, 112, 115–117
Dimensional Assessment of Personality Pathology, 755
Dimensional Assessment of Personality Problems, 744
Dissociation Questionnaire (DIS-Q), 421
Dissociative Disorders Interview Schedule (DDIS), 417–419
Dissociative Experiences Scale (DES), 418–419
Dissociative Experiences Scale-Taxon (DES-T), 420
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic and assessment tools (Continued)</td>
</tr>
<tr>
<td>Drug Abuse Screening Test (DAST), 660, 678</td>
</tr>
<tr>
<td>Drug-Taking Confidence Questionnaire-8 (DTCQ-8), 651</td>
</tr>
<tr>
<td>Drug Use Disorders Identification Test (DUDIT), 678</td>
</tr>
<tr>
<td>Drug Use Screening Inventory (DUSI), 680, 681</td>
</tr>
<tr>
<td>Eating Attitudes Test (EAT), 497</td>
</tr>
<tr>
<td>Eating Disorder Examination (EDE), 479, 478, 479</td>
</tr>
<tr>
<td>Eating Disorder Examination-Questionnaire (EDE-Q), 479, 480</td>
</tr>
<tr>
<td>Eating Disorder Inventory (EDI), 479-480</td>
</tr>
<tr>
<td>Eating Disorder Inventory-2 (EDI-2), 479</td>
</tr>
<tr>
<td>Eating Disorder Inventory-3 (EDI-3), 479-480</td>
</tr>
<tr>
<td>Family Environment Scale, 179</td>
</tr>
<tr>
<td>Family Experiences Interview Schedule, 179-180</td>
</tr>
<tr>
<td>Fear of Negative Evaluation Scale (FNE), 139</td>
</tr>
<tr>
<td>Fear Survey Schedule-Second Edition (FSS-II), 141, 317</td>
</tr>
<tr>
<td>Feminine Gender Identity Scale for Males, 613</td>
</tr>
<tr>
<td>Form 90D, 680</td>
</tr>
<tr>
<td>functional analysis, 677, 681, 692</td>
</tr>
<tr>
<td>Gender Identity/GD Questionnaire for Adolescents and Adults, 613</td>
</tr>
<tr>
<td>General Behavior Inventory (GBI), 229</td>
</tr>
<tr>
<td>General Health Questionnaire (GHQ), 271-272</td>
</tr>
<tr>
<td>Generalized Anxiety Disorder Questionnaire-DSM-IV (GAD-Q-IV), 316</td>
</tr>
<tr>
<td>Geriatric Depression Scale (GDS), 270</td>
</tr>
<tr>
<td>Gudjonsson Suggestibility Scale (GSS), 432</td>
</tr>
<tr>
<td>hair analyses, 653, 682</td>
</tr>
<tr>
<td>Hamilton Anxiety Rating Scale, 114</td>
</tr>
<tr>
<td>Hamilton Rating Scale for Depression, 114, 650</td>
</tr>
<tr>
<td>Haptic Illusion, 494-495</td>
</tr>
<tr>
<td>Health Anxiety Questionnaire, 460</td>
</tr>
<tr>
<td>Health Attitude Survey, 460</td>
</tr>
<tr>
<td>Hoarding Rating Scale-Interview (HRS-I), 361</td>
</tr>
<tr>
<td>Hoarding Rating Scale-Self Report (HRS-SR), 363</td>
</tr>
<tr>
<td>Hospital Anxiety and Depression Scale (HADS), 271</td>
</tr>
<tr>
<td>Hypomanic Personality Scale, 229</td>
</tr>
<tr>
<td>Intelligence Quotient (IQ), 19-20</td>
</tr>
<tr>
<td>International Personality Disorder Examination (IPDE), 111, 113, 121-123</td>
</tr>
<tr>
<td>Interview for Diagnosis of Eating Disorders (IDED), 478</td>
</tr>
<tr>
<td>Interview for Diagnosis of Eating Disorders-IV (IDED-IV), 479</td>
</tr>
<tr>
<td>Inventory of Drug Use Consequences (InDUC), 680, 681</td>
</tr>
<tr>
<td>Inventory of Personality Organization, 756</td>
</tr>
<tr>
<td>Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS), 232</td>
</tr>
<tr>
<td>LEAD (Longitudinal, Expert, All Data) standard, 756</td>
</tr>
<tr>
<td>life-charting strategies, 232, 543</td>
</tr>
<tr>
<td>lifetime drinking history (LDH), 649</td>
</tr>
<tr>
<td>Maryland Assessment of Social Competence (MASC), 178</td>
</tr>
<tr>
<td>Masculine Gender Identity Scale for Females, 613</td>
</tr>
<tr>
<td>Massachusetts General Hospital Hairpulling Scale (MGH-HPS), 361</td>
</tr>
<tr>
<td>Milon Clinical Multiaxial Inventory-III, 650, 678</td>
</tr>
<tr>
<td>Milwaukee Inventory for Subtypes of Trichotillomania-Adult Version (MIST-A), 361</td>
</tr>
<tr>
<td>Milwaukee Inventory for the Dimensions of Adult Skin Picking (MIDAS), 361</td>
</tr>
<tr>
<td>Mini-International Neuropsychiatric Interview (MINI), 273-274</td>
</tr>
<tr>
<td>Mini-International Neuropsychiatric Interview-Screen (MINI-Screen), 271</td>
</tr>
<tr>
<td>Minnesota Multiphasic Personality Inventory, 10</td>
</tr>
<tr>
<td>Minnesota Multiphasic Personality Inventory-2, 613, 650</td>
</tr>
<tr>
<td>Montgomery Asberg Depression Rating Scale (MADRS-S), 270</td>
</tr>
<tr>
<td>Multiaxial Assessment of Eating Disorder Symptoms (MAEDS), 480</td>
</tr>
<tr>
<td>Multidimensional Inventory of Dissociation (MID), 420</td>
</tr>
<tr>
<td>Multiphasic Sex Inventory, 579</td>
</tr>
<tr>
<td>Multiple Sleep Latency Test (MSLT), 525-526, 530</td>
</tr>
<tr>
<td>NEO Personality Inventory-Revised (NEO PI-R), 17</td>
</tr>
<tr>
<td>NIMH-Life Charting method, 322</td>
</tr>
<tr>
<td>NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS), 177</td>
</tr>
<tr>
<td>observational tasks, 360</td>
</tr>
<tr>
<td>Obsessive-Compulsive Inventory (OCI), 360</td>
</tr>
<tr>
<td>Panic and Agoraphobia Scale (PAS), 316</td>
</tr>
<tr>
<td>Panic Disorder Severity Scale (PDSS), 316</td>
</tr>
<tr>
<td>Patient Health Questionnaire-9 (PHQ-9), 270, 271</td>
</tr>
<tr>
<td>Patient Health Questionnaire-15, 460</td>
</tr>
<tr>
<td>Penn State Worry Questionnaire (PSWQ), 316</td>
</tr>
<tr>
<td>Personality Disorder Questionnaire, 754</td>
</tr>
<tr>
<td>phallometry, 580-581</td>
</tr>
<tr>
<td>Phobic Stimuli Response Scales, 317</td>
</tr>
<tr>
<td>polygraph testing, 581</td>
</tr>
<tr>
<td>Positive and Negative Affect Scales Expanded Form (PANAS-X), 140-141</td>
</tr>
<tr>
<td>Posttraumatic Diagnostic Scale (PDS), 393</td>
</tr>
</tbody>
</table>
Subject Index 825

Primary Care Evaluation of Mental Disorders (PRIME-MD), 270–271
Profile of Mood States (POMS), 270
Psychodynamic Diagnostic Manual (PDM), 756
Psychotic Rating Scale (PSYRATS), 177
PTSD Checklist, 393
PTSD Symptom Scale–Interview (PSS-I), 392
PTSD Symptom Scale–Self Report (PSS-SR), 393
Quick Inventory of Depressive Symptomatology (QIDS), 271
Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR), 45
Rorschach Ink blot Method, 756
saliva analysis, 682
Saving Inventory-Revised (SI-R), 361
Scale for the Assessment of Negative Symptoms, 177
Scale for the Assessment of Positive Symptoms, 177
Schedule for Affective Disorders and Schizophrenia (SADS), 111, 112, 117–118
Schedule for Nonadaptive and Adaptive Personality, 744, 755
Schedules for Clinical Assessment in Neuropsychiatry, 459
Screening for Somatoform Symptoms, 460
Set Flexibility Picture Test, 495
Severity of Alcohol Dependence Questionnaire (SADQ), 650
Sexual Deviance Card Sort, 579
Sexual Interest Card Sort Questionnaire, 579
Shedler and Westen Assessment Procedure (SWAP), 755–756
Short Alcohol Dependence Data Questionnaire (SADD), 650
Simple Screening Instrument for Substance Abuse (SSI-SA), 679
Situational Confidence Questionnaire (SCQ-39), 651
Skin Picking Scale (SPS), 361
Social Avoidance and Distress Scale (SAD), 139
Social Functioning Scale, 179
Social Interaction Anxiety Scale (SIAS), 316
Social Interaction Scale (SIAS), 141
Social Phobia and Anxiety Inventory (SPAI), 316
Social Phobia and Anxiety Inventory for Children (SPAI-C), 316
Social Phobia Scale (SPS), 141, 316
Somatoform Disorders Schedule, 459
Somatoform Dissociation Questionnaire (SDQ), 420–421
Spence Child Anxiety Scale, 317
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES), 681
State Scale of Dissociation (SSD), 421
Stirling Eating Disorder Scales (SEDS), 480
Structured Clinical Interview for DSM (SCID), 171
Structured Clinical Interview for DSM-5 Disorders, 120, 464–465, 679
Structured Clinical Interview for DSM-IV, 51, 236, 272–273, 393, 417, 459, 478
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), 111, 112, 118–120, 232, 315–316
Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II), 111, 113, 123–124
Structured Clinical Interview for DSM-IV-Revised (SCID-D-R), 417
Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-CV), 360, 361
Structured Clinical Interview for DSM-IV-TR Axis II Personality Disorders (SCID-II), 754
Structured Interview for Anorexic and Bulimic Disorders (SIAB-EX), 478, 479
Structured Interview for DSM-IV Personality (SIDP-IV), 111, 113, 124–125
Structured Interview for PTSD (SI-PTSD), 392
Structured Interview of Personality Organization, 756
Substance Dependence Severity Scale (SDSS), 679
Symptom Checklist 90-Revised (SCL-90-R), 139, 460, 650
Temperament Evaluation of Memphis, Pisa, Paris, and San Diego (TEMPS-A), 229
Thematic Apperception Test, 756
Three Factor Eating Questionnaire (TFEQ), 480
Timeline Followback (TLFB), 649, 660, 680
Trail Making Test (TMT), 494–495, 651
UCSD Performance-Based Skills Assessment (UPSA), 179
University of Rhode Island Change Assessment (URICA), 681
urinalyses, 652–653, 681–682
Utrecht GD Scale, 613
Uznadze Illusion Task, 495
visual reaction time, 581
Wechsler Adult Intelligence Scale, 431
Wechsler Adult Intelligence Scale (WAIS-III), 651
Diagnostic and assessment tools (Continued)

Wechsler Memory Scale (WMS-III), 651
Whiteley Index, 460, 465
Wilson Sex Fantasy Questionnaire, 579
Wisconsin Card Sorting Task (WCST), 494, 651
World Health Organization (WHO) Composite International Diagnostic Interview (CIDI), 10, 47, 116, 273, 459, 478
World Health Organization Well-Being Index (WHO-WBI), 271–272
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), 360
Yale-Brown Obsessive-Compulsive Scale-BDD (Y-BOCS-BDD), 361
Yale-Brown Obsessive-Compulsive Scale-Second Edition (Y-BOCS-II), 360
Yale-Brown Obsessive-Compulsive Scale-Self Report, 360
Zung Depression Scale, 270
Zung Self-Rating Depression Scale, 10

Diagnostic and Statistical Manual of Mental Disorders (DSM):

alcohol use disorders in, 641–642
anxiety disorders in, 299–306
bipolar disorder in, 217–219, 228, 229–230
dimensional vs. categorical classification in, 3–24, 228–229, 305, 390, 451–452, 758
dissociative disorders in, 407–408, 410–415, 417, 421
DSM-I, 644, 746
DSM-II, 414, 746
DSM-II-R, 53

DSM-III, 4, 5, 8, 15, 22, 24, 301, 457, 603–604, 739, 747, 749, 757
DSM-III-R, 5, 6, 8, 15, 266, 301, 305, 457, 604–605, 644, 747
dual diagnosis based on, 37–41, 43, 51, 53, 67, 80
epidemiological studies based on, 266
feeding and eating disorders in, 473, 474–477
gender dysphoria in, 547, 603–605, 606, 609–612
multixial system removal from, 103, 111, 124
neurocognitive disorders in, 706–707, 710–711, 720
obessive-compulsive disorder in, 355–356, 358–361
personality disorders in, 739–745, 746–763
racial, ethnic and cultural factors considered in, 141–143, 146–147, 151
schizophrenia in, 170
sexual dysfunctions and paraphilic disorders in, 547–552, 557, 569–576
sleep disorders in, 523, 526–532, 541–542
somatic symptom and related disorders in, 451–452, 456–457, 459, 461, 466
substance use disorders in, 641–642, 644, 649–650, 675–676
trauma- and stress-related disorders in, 387–389, 390, 391, 392–393, 397, 399

Dialectical behavior therapy (DBT):
for dissociative disorders, 423
for feeding and eating disorders, 493
for obsessive-compulsive disorders, 372–373
for personality disorders, 753

Differential diagnosis:
of anxiety disorders, 305–306
of attention deficit/hyperactivity disorder, 231
of bipolar disorder, 173, 228–232
of clinical disorders, generally, 103, 111, 112, 113–120
of delusional disorder, 174–175
of depressive disorders, 173, 260–262, 719–720
dimensional vs. categorical classification, 3, 5
depr of feeding and eating disorders, 475–477
depr of gender dysphoria, 610
depr of obsessive-compulsive disorders, 358–359
depr of personality disorders, 103, 105, 111, 112–113, 117, 120–125, 759–760
depr of schizoaffective disorder, 173–174
of schizophrenia, 171–175
Dissociative disorders:
Dissociative amnesia:
Disruptive behavior disorders.
See Conduct or disruptive behavior disorders
Disruptive mood dysregulation disorder (DMDD), 229–230
Dissociative amnesia:
continuous, 410
crime-related, 411
description of, 407, 409,
410–413
diagnostic considerations
for, 412–413
dissociative fugue
and, 412–413
epidemiology of, 410–413
generalized, 410
localized, 410
posttraumatic vs. sociocognitive
model of, 431–432
psychological assessments
of, 420, 421
selective, 410
systematized, 410
Dissociative disorders:
age influences and differences
in, 411, 414
biological considerations
for, 424–426
borderline personality disorder
comorbidity with, 415, 430
case study of, 422–423
cognitive-behavioral therapy
for, 423, 435
cognitive functioning
with, 430–433
compartmentalization in, 409
coping skills training for, 423
depersonalization/
derealization disorder
as, 408, 409, 412–414, 418,
420, 421, 425–426, 434–435
depressive disorder comorbidity
with, 416
description of, 407–410
detachment in, 409
diagnostic considerations
for, 412–414, 415–416, 436
dialectical behavior therapy
for, 423
dimensional vs. categorical
classification of, 7
dissociative amnesia as, 407,
409, 410–413, 420, 421,
431–432
dissociative fugue as, 412–413
dissociative identity disorder
as, 408, 409, 414–417,
417–436, 610
eating disorder comorbidity
with, 416
environmental risk factors
for, 423–424, 426–427
epidemiology of, 408, 410–412,
413, 414, 416–417
etiological considerations
for, 409–410, 423–427, 436
gender dysphoria comorbidity
with, 610
gender influences and differences
in, 414, 416–417
genetic risk factors
for, 423–424
hypnosis with, 422, 430, 432
learning and modeling of,
427
mindfulness approaches
for, 423
neurobiological function
in, 424–426, 431
other specified dissociative
disorder as, 408
pharmacologic interventions
for, 434–435
posttraumatic model of disso-
ciation, 407, 408, 409, 416,
418, 427–435
psychological assessments
of, 417–422, 423
racial, ethnic and cultural fac-
tors in, 143, 412–413, 430
schizoaffective disorder
comorbidity with, 416
schizophrenia comorbidity
with, 416
self-report measures
on, 419–422
sexual disorder comorbidity
with, 416
sleep disorder comorbidity
with, 416, 433–434, 436
sociocognitive model of
dissociation, 427–435
somatic dissociation, 409, 420
structured and semistructured
interviews on, 417–418
substance-induced
dissociation, 424
substance use comorbidity
with, 416
suicide/suicide ideation
comorbidity with, 416, 435
symptom overlap with, 414,
413, 610
treatments and interventions
for, 423, 434–435
unspecified dissociative dis-
order as, 408
Dissociative fugue, 412–413
Dissociative identity disorder
(DID):
biological considerations
for, 424–426
case study of, 422–423
cognitive functioning
with, 430–433
description of, 408, 409,
414–417
diagnostic considerations
for, 415–416
environmental risk factors
for, 423–424, 426–427
epidemiology of, 416–417
etiological considerations
for, 423–427
gender dysphoria comorbidity
with, 610
genetic risk factors
for, 423–424
posttraumatic vs. sociocognitive
model of, 427–435
psychological assessments
of, 417–422, 423
treatments and interventions
for, 423, 435
Drug interventions. See Pharma-
cologic interventions
Drug use disorders. See also
Substance use disorders
age influences and differences
in, 676–677, 689–690
anxiety disorder comorbidity
with, 676, 688
bipolar disorder comorbidity
with, 231
cannabinoids in, 673–674
case study of, 691–692
Drug use disorders (Continued)
central nervous system depressants in, 674
clinical picture of, 673–675
cognitive functioning with, 57–58, 687–688
coping skills training for, 677, 681
costs of, 673
course and prognosis of, 689–691
depressive disorder comorbidity with, 263–264, 676, 688, 691–692
description of, 673
diagnosis and assessment impacted by, 67–70
diagnostic considerations for, 673–676
dimensional vs. categorical classification of, 39–40
dissociative anesthetics in, 674
drug-induced dissociation, 424
environmental risk factors for, 686–687
epidemiology of, 676–677
etiological considerations for, 682–689
feeding and eating disorder comorbidity with, 688
gender influences and differences in, 688
 genetic risk factors for, 682–684
hallucinogens in, 673–674
inhalants in, 674–675
learning and modeling of, 686–687
life functioning with, 675, 677
neurobiological function in, 675, 684–686
neurocognitive disorders association with, 729
opioids in, 674
other substance use comorbidity with, 645
personality disorder comorbidity with, 676
physical illnesses associated with, 63
prescription drugs in, 674
psychological and biological assessments of, 677–682
psychopathology research impacted by, 69–71
racial, ethnic and cultural factors in, 134, 143, 154, 689
schizophrenia comorbidity with, 676
secondary substance abuse models on, 75–77
severity rating of, 675–676
social functioning with, 675
structured and semistructured interviews on, 679–681
trauma- and stress-related disorder comorbidity with, 685–686, 688
 treatments and interventions for, 677, 681, 688–689, 690–691
treatments and interventions for, 66
violence associated with, 59
withdrawal symptoms with, 673, 674, 675
Dual diagnosis. See also Comorbidity

Comorbidity

bidirectional models on, 79–80
clinical impacts of, 54–66
clinical studies of, 36, 48–54
common factors models on, 72–74
community sample prevalence of, 41–43
complexity of, 44–45, 51, 60, 80–81
conduct or disruptive behavior disorders in, 73, 74
cross-national epidemiological studies of, 47
diagnosis and assessment impacted by dual disorders, 66–70, 456–457
epidemiological studies of, 36, 41–48
expanding and changing concepts of, 45–48
feeding and eating disorders in, 50, 51, 52
functioning relationship to, 54–60, 67, 73–74, 76
future directions in, 80–81
gambling disorders in, 40, 48
gender dysphoria in, 610–612
genetic risk factors for, 72–73, 74
health-care costs impacted by, 61
homelessness associated with, 64
legal problems or criminality as factor in, 39, 55, 64, 73
methodological issues in, 36–41
obsessive-compulsive disorders in, 42, 47, 50, 53
older adults with, 47–48
overview of, 35–36
persistence over time, 43–44, 48
personality disorders in, 41, 42, 47, 48, 50–51, 53, 55, 66, 69, 70, 73
physical illness risks in, 62–64, 81
psychopathology research impacted by, 69–71, 81
psychoses or psychotic disorders in, 45, 48, 58
sample selection influencing findings for, 36–37, 70–71
schizophrenia in, 42, 46, 48–49, 51–52, 54, 55, 56, 57–58, 59–60, 63, 64, 67, 73, 75, 76–77, 77–78
secondary psychiatric disorder models on, 78–79
secondary substance abuse models on, 74–78
service utilization impacted by, 60–62
single definition of, lack of, 37–41
somatic symptom and related disorders in, 456–457
structured interviews for, 36, 37, 51
study methods and assessment measures influencing findings for, 37

828 Subject Index
Environmental risk factors:
- Eating disorders.
- Early onset dysthymia, 7
- Dysthymic disorder.
- Dyspareunia, 551, 560, 566
- Epidemiologic Catchment Area for sleep disorders, 531
- for sexual dysfunctions and for schizophrenia, 179
- for obsessive-compulsive disorders, 424, 426–427
- for dissociative disorders, 482–483, 491–494
- for gender dysphoria, 620, 623–624
- for dissociative disorders, 423–424, 426–427
- for eating and eating disorders, 299, 268–269, 279–280
- for personality disorders, 750–751, 753
- for schizophrenia, 179–180, 182–183, 184–185, 192
- for sexual dysfunctions and paraphilic disorders, 583
- for sleep disorders, 531–532, 537
- for somatic symptom and related disorders, 461
- for substance use disorders, 394, 652, 653–654, 655–656, 668–687
- for trauma and stress-related disorders, 394, 395–396
- for bipolar disorder, 223–224
- for depressive disorders, 259, 268–269, 279–280
- for depression, 274–281
- for dissociative disorders, 409–410, 423–427, 436
- for feeding and eating disorders, 481–497
- for gender dysphoria, 619–625
- for neurocognitive disorders, 723–732
- for obsessive-compulsive disorders, 362–372
- for personality disorders, 750–752
- for suicide, 557–561, 581–583, 621
- for sleep disorders, 531–532, 537–538
- for somatic symptom and related disorders, 460–462
- for substance use disorders, 72–74, 653–658, 682–689, 728–729
- for trauma and stress-related disorders, 393–397
- European Outcome of Depression International Network, 392
- Factitious disorder, 451, 455
- Family assessments, for schizophrenia, 179–180
- Family-focused therapy (FFT): for bipolar disorder, 226, 227, 228
- for feeding and eating disorders, 497–498
- Feeding and eating disorders: age influences and differences in, 474, 477, 497

Erectile disorder (ED):
- clinical picture of, 550
- course, prognosis and treatment for, 563–564
- description of, 549
- epidemiology of, 555
- etiological considerations for, 558–559
- psychological and biological assessments of, 556
- EROS Clitoral Therapy
- Device, 563, 566
- Estonian Children Personality, Behaviour and Health Study, 493
- Ethnicity. See Racial, ethnic and cultural factors
- Etiological considerations:
- for anxiety disorders, 318–331
- for bipolar disorder, 232–234
- for depressive disorders, 274–281
- for dissociative disorders, 409–410, 423–427, 436
- for feeding and eating disorders, 481–497
- for gender dysphoria, 619–625
- for neurocognitive disorders, 723–732
- for obsessive-compulsive disorders, 362–372
- for personality disorders, 750–752
- for schizophrenia, 181–190
- for sexual dysfunctions and paraphilic disorders, 557–561, 581–583, 621
- for sleep disorders, 531–532, 537–538
- for somatic symptom and related disorders, 460–462
- for substance use disorders, 72–74, 653–658, 682–689, 728–729
- for trauma and stress-related disorders, 393–397
- diagnostic considerations for, 359
- environmental risk factors for, 363–364, 367
- epidemiology of, 360
- gender influences and differences in, 371
- genetic risk factors for, 363–364
- neurobiological function with, 366, 369
- psychological and biological assessments of, 361
- racial, ethnic and cultural factors in, 371
- structured and semistructured interviews on, 120
- treatments and interventions for, 373
- Exhibitionistic disorder, 569–570, 576, 577, 584–585
- Exposure therapy:
- for anxiety disorders, 311–312, 314
- for obsessive-compulsive disorders, 371–372
- Prolonged Exposure as, 397
- racial, ethnic and cultural variations of, 142
- for trauma- and stress-related disorders, 397–398
- Eye movement desensitization and reprocessing (EMDR), 313

Subject Index  829
Feeding and eating disorders (Continued)

anxiety comorbidity with, 476, 497
atypical anorexia nervosa, 475
avoidant/restrictive food intake disorder as, 473
bipolar disorder comorbidity with, 51
case study of, 499–501
clinical picture of, 473–475
cognitive-behavioral therapy for, 498, 499
cognitive functioning with, 494–496
coping skills training for, 493
costs of, 498
course and prognosis of, 497–499
depression comorbidity with, 476, 497
description of, 473
diagnostic considerations for, 475–477
dialectical behavior therapy for, 493
dimensional vs. categorical classification of, 7
dissociative disorder comorbidity with, 416
dual diagnosis including, 50, 51, 52
environmental risk factors for, 482–485, 491–494
epidemiology of, 477
epiological considerations for, 481–497
family-based therapy for, 497–498
future research in, 501
gender influences and differences in, 474, 477, 482
genetic risk factors for, 482, 483–486, 493
hospitalization for, 498
interpersonal therapy for, 498, 499
learning and modeling of, 491–494
life functioning with, 476
neurobiological function for, 481–490, 495
night eating syndrome, 475
obesity and, 475, 476–477, 481, 486, 487–488, 499, 501
other specified feeding or eating disorder (OFSED), 475, 476, 479
personality disorder comorbidity with, 476
personality traits with, 476, 483, 486
pharmacologic interventions for, 498, 499
physical illnesses and mortality associated with, 480–481, 497, 498–499
pica as, 473
posttraumatic stress disorder comorbidity with, 493, 500–501
psychological and biological assessments of, 477–481
purging disorder as, 475
racial, ethnic and cultural factors in, 133, 143, 144, 477, 482–483, 496–497
rumination disorder as, 473
structured and semistructured interviews on, 478–479
substance use comorbidity with, 50, 52, 476, 488
treatments and interventions for, 493, 497–499
Female orgasmic disorder (FOD): clinical picture of, 550
course, prognosis and treatment for, 565–566
description of, 549
epidemiology of, 556
etiological considerations for, 560
Female sexual interest/arousal disorder (SIAD): clinical picture of, 550–551
course, prognosis and treatment for, 561–563
description of, 549
epidemiology of, 555
etiological considerations for, 558, 559
psychological and biological assessments of, 557
Fetishistic disorder, 570, 576, 577
 Fibromyalgia, 461
“Frenzy” witchcraft, as culture-bound syndrome, 413
Frontotemporal neurocognitive disorder, 707, 711–712
Fracture disorder, 570–571, 576, 577
Functional neurological symptom disorder. See Conversion disorder
Functioning:
cognitive functioning (see Cognitive functioning)
community functioning, 179
dual diagnosis relationship to, 54–60, 67, 73–74, 76
life functioning (see Life functioning)
neurobiological function (see Neurobiological function)
social functioning (see Social functioning)
Galen, 745
Gambling disorders:
age influences and differences in, 48
diagnostic and assessment tools addressing, 120
dimensional vs. categorical classification of, 7, 12
dual diagnosis including, 40, 48
Gender dysphoria:
acceptance of natal gender in, 615
affective and adjustment disorder comorbidity with, 611
age influences and differences in, 606, 613
anxiety comorbidity with, 613
bipolar disorder comorbidity with, 610
case study of, 625–627
clinical picture of, 605–609
cognitive functioning with, 624
course and prognosis of, 614–616
depression comorbidity with, 605, 626–627
description of, 603–605
diagnostic considerations for, 609–612

 disorders of sexual development as, 606, 614

dissociative disorder comorbidity with, 610

environmental risk factors for, 620, 623–624

epidemiology of, 612–613

etiological considerations for, 619–625

 full-time cross-living in, 615–616

gender influences and differences in, 606, 607–609, 612, 624–625

genetic risk factors for, 619–621

 history and terminology of, 603–605

 homosexual females with, 607, 609, 613, 626

 homosexual males with, 607–608, 613, 622, 625

 hormone therapy for, 610, 612, 615, 616–617, 621, 624–625, 626

 intersexual condition, 606

 karyotyping in, 614

 learning and modeling of, 623–624

 neurobiological function in, 621–623

 nonhomosexual females with, 607, 609, 613

 nonhomosexual males with, 607, 608–609, 610, 613, 615, 621–622, 625

 other specified, 609

 part-time cross-gender behavior in, 615

 personality disorder comorbidity with, 610, 611

 psychological and biological assessments of, 613–614

 psychoses or psychotic disorder comorbidity with, 610, 613

 psychotherapy for, 616, 626

 racial, ethnic and cultural factors in, 625

 real-life experience in desired gender role in, 617–618

 schizophrenia comorbidity with, 610

 sex reassignment for, 603, 605, 608–609, 612, 614, 615–616, 618–619, 625

 sexual dysfunctions and paraphilic disorders comorbidity with, 574, 576, 605, 608, 609, 610, 612–613, 615, 624

 sexual dysfunctions and paraphilic disorders separation from, 547

 sexual orientation and, 607–609, 613, 621–622, 624, 625, 626

 standards of care for, 616

 stigmatization of, 611

 transsexualism as, 603

 transvestic disorder association with, 574, 576, 608, 609, 610, 612–613, 615

 treatments and interventions for, 603, 605, 608–609, 610, 612, 614, 615–619, 621, 624–625, 626

 unresolved or unknown outcomes in, 615

 unspecified, 609

 Gender influences and differences. See also Women in anxiety disorders, 306, 307, 308, 309

 in bipolar disorder, 220

 in depressive disorders, 266–267, 280–281

 in dissociative disorders, 414, 416–417

 in feeding and eating disorders, 474, 477, 482

 in gender dysphoria, 606, 607–609, 612, 624–625

 in obsessive-compulsive disorders, 369–371

 in paraphilic disorders, 570, 571–572, 573, 574–575, 577, 578–579

 in schizophrenia, 186–187, 191

 in sexual dysfunction (see gender-specific sexual dysfunctions) in sleep disorders, 529, 534

 in somatic symptom and related disorders, 458, 462

 in substance use disorders, 36, 64–65, 646, 647, 654, 657–658, 659, 688

 in trauma- and stress-related disorders, 396

 Generalized anxiety disorder. See also Anxiety disorders behavioral considerations for, 323–326

 biological/neurobiological function with, 319–322

 bipolar disorder comorbidity with, 231

 cognitive-behavioral therapy for, 311, 313–314

 cognitive functioning with, 326–329

 depression comorbidity with, 265, 307–308, 315

 description of, 301–303

diagnostic considerations for, 305

 dual diagnosis including, 51

 emotion dysregulation in, 303

 epidemiology of, 307–308

 etiological considerations for, 318–331

 genetic risk factors for, 318–319, 322

 hoarding disorder comorbidity with, 359

 intolerance of uncertainty in, 302

 personality and temperament in, 323

 pharmacologic interventions for, 310, 313–314

 racial, ethnic and cultural factors in, 136

 self-monitoring of, 317

 self-report measures for, 315–316

 sleep disorder comorbidity with, 528

 structured and semistructured interviews on, 315–316

 substance use comorbidity with, 51

 treatments and interventions for, 310, 311, 313–315

 Genetic risk factors:

 for anxiety disorders, 318–319, 322

 for bipolar disorder, 73, 232–233, 234
ICD-6, 644
ICD-10, 14–15, 37–38, 121–123, 142, 273, 304, 421, 459, 479, 605, 642, 644, 676
ICD-11, 547
personality disorders in, 763
racial, ethnic and cultural factors considered in, 142
sexual dysfunctions and paraphilic disorders in, 547
structured and semistructured interviews based on, 121–123, 273, 459, 479
substance use disorders in, 642, 644, 676
International Classification of Sleep Disorders (ICSD-2), 523, 526, 531
International College of Obsessive Compulsive Spectrum Disorders (ICOCOS), 371
Internet addiction, 12
Interpersonal therapy (IPT): for anxiety disorders, 313
for bipolar disorder, 226, 227
for feeding and eating disorders, 498, 499
interpersonal and social rhythm therapy (IPSRT) as, 226, 227
Interventions. See Treatments and interventions
Interviews. See Structured and semistructured interviews
Item response theory (IRT) methodology, 13–14, 39–40
Jellinek, E. M., 643
Karyotyping, 614
Kleine-Levin syndrome, 529, 530, 535
Kleinfelter syndrome, 614
Koro, as culture-bound syndrome, 142
Kraepelin, Emil, 745–746, 763
Kuru, 731
Legal problems. See also Criminality
consensual paraphilias not legal issue, 575
dual diagnosis consideration of, 59, 55, 64, 73
sexual offenders and paraphilias, 569, 570, 571, 572, 577, 578, 579–580, 583–585
substance use disorders and, 39, 55, 64, 73, 642
Leukoaraiosis, 720
Lewy bodies disease, 707, 712
Life events. See Environmental risk factors
Life functioning: anxiety disorders impacting, 299
bipolar disorder impacting, 221–222
depressive disorders impacting, 261–262
dual diagnosis impacting, 55–56
feeding and eating disorders impacting, 476
obsessive-compulsive disorder impacting, 357
schizophrenia impacting, 55, 165, 166, 175–176
sleep disorders impacting, 527, 528
somatic symptom and related disorders impacting, 452, 453
substance use disorders impacting, 55–56, 646, 660, 675, 677
Longitudinal Study of Personality Disorder, 753
MacArthur Risk Assessment Study, 169
Major depressive disorder, 254, 255–256, 282–283. See also Depressive disorders
Male hypoactive sexual desire disorder, 549, 551–552, 558, 561
Maltreatment. See Physical and sexual abuse
Mania. See Bipolar disorder
Masochism. See Sexual masochism disorder
McLean Study of Adult Development (MSAD), 753
Medical assessments. See Biological assessments
Medical illnesses. See Physical illnesses
Meditation, 312
Men. See also Gender influences and differences
delayed ejaculation in, 549–550, 555–556, 559–560, 565
erectile disorder in, 549, 550, 555, 556, 558–559, 563–564
gender dysphoria in, 547, 574, 576, 603–627
male hypoactive sexual desire disorder in, 549, 551–552, 558, 561
paraphilic disorders in, 570, 571–572, 573, 574–575, 577, 578–579
premature (early) ejaculation in, 549, 552, 555, 557, 559, 565
substance use among, specifically, 657–658, 659, 688
Mental disorders: anxiety (see Anxiety disorders)
autistic, 7
bipolar (see Bipolar disorder)
comorbidity of (see Comorbidity)
conduct or disruptive behavior (see Conduct or disruptive behavior disorders)
costs associated with (see Health-care costs)
depressive (see Depressive disorders)
diagnosis of (see Diagnosis and assessment)
dissociative (see Dissociative disorders)
feeding and eating (see Feeding and eating disorders)
gender dysphoric (see Gender dysphoria)
impulse-control, 14, 16, 355, 358
intellectual, 13, 19–20, 711, 731, 732–733
obsessive-compulsive (see Obsessive-compulsive anxiety disorders; Obsessive-compulsive personality disorders)
personality (see Personality disorders)
psychotic (see Psychoses or psychotic disorders)
Mental disorders (Continued)

rational, ethnic and cultural factors in (see Racial, ethnic and cultural factors)
schizophrenic (see Schizophrenia)
school (see Sexual dysfunctions and paraphilic disorders)
sleep-related (see Sleep disorders)
somatic (see Somatic symptom and related disorders)
stigma associated with (see Stigmatization)
substance use (see Substance use disorders)
trauma- and stress-related (see Trauma-and-stress-related disorders)
treatment for (see Treatments and interventions)

Mentalization-based therapy, 753
Mental retardation. See Intellectual disability
Mayer, Adolf, 746
Microcephaly, 20
Mindfulness approaches:
for anxiety disorders, 312–313
for dissociative disorders, 423
for sexual dysfunctions and paraphilic disorders, 563, 566
Minorities, issues for. See Racial, ethnic and cultural factors
Monitoring the Future Study, 677
Mood disorders. See Bipolar disorder; Depressive disorders; Disruptive mood dysregulation disorder
Mosaic, 20
Motivational interventions:
for sleep disorders, 530
for substance use disorders, 644, 648, 659, 661
Multiple personality disorder. See Dissociative identity disorder
Multiple sclerosis, 456, 720, 727, 731
Munchausen by proxy, 143
Narcissistic personality disorder:
clinical picture of, 748
dual diagnosis including, 47
epidemiology of, 749, 750

etiological considerations for, 750, 751
psychological assessments of, 757
separation of personality pathology and, 745
substance use comorbidity with, 47
Narcolepsy, 523, 527–528, 529, 530, 531, 542
Narcotics Anonymous (NA), 692
National Center for PTSD, 393
National Coalition for Sexual Freedom, 575
National Comorbidity Survey (NCS), 9, 10, 41, 42, 43–44, 45, 61, 262, 266, 457
National Comorbidity Survey Replication (NCS-R), 41, 42, 43, 45, 47, 48, 262, 266–268, 358, 391, 392, 476
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 42, 44, 47, 48, 50–51, 59, 646
National Health and Social Life Survey (NHSLS), 553–554, 555, 556
National Institute for Clinical Excellence (NICE), 497
National Institute for Drug Abuse, 681
National Institute of Mental Health (NIMH):
classification by, 4, 23
Collaborative Program/Study on the Psychobiology of Depression, 49, 55
Collaborative Study of Depression, 49, 55
Course and Outcome of Bipolar Youth (COBY) study by, 230
DSM-5 criticism by, 23–24
Life Charting method, 232
Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS), 177
Research Domain Criteria (RDoC) of, 23
structured interviews developed for, 115
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 646, 648
National Institute on Drug Abuse Collaborative Cocaine Treatment Study, 53
National Institutes of Health (NIH) Joint Program for the Diagnosis and Classification of Mental Disorders, 121
National Latino and Asian Study (NLSA), 132, 153, 268
National Longitudinal Alcohol Epidemiological Survey (NLAS), 41, 42, 44, 60, 154, 646
National Research Act, 152
National Survey of American Life (NSAL), 144, 268
National Survey of Veterans, 63
Neurasthenia, as culture-bound syndrome, 142–143
Neurobiological function. See also Cognitive functioning in anxiety disorders, 318, 319–322
in bipolar disorder, 233–235, 431
in conversion disorder, 451, 454, 458, 461
in depressive disorders, 276–277, 719–720
in dissociative disorders, 424–426, 431
dual diagnosis impacted by, 76
in feeding and eating disorders, 486–490, 495
in gender dysphoria, 621–623
neurocognitive disorders impacting, 705–734
in obsessive-compulsive disorders, 364–366, 368–369
in personality disorders, 751
in schizophrenia, 76–77, 180–181, 183–184, 431
in sexual dysfunctions and paraphilic disorders, 558, 559–560, 582, 621
in sleep disorders, 524–526, 529, 531, 536, 538, 539
in somatic symptom and related disorders, 461
in substance use disorders, 651, 654–655, 675, 684–686, 728
in trauma- and stress-related disorders, 394–395, 685–686
Neurocognitive disorders:

calculias as, 715
age influences and differences in, 711, 713, 720, 721, 727, 732–733
agnosias or gnostic disorders as, 707, 715, 716
agraphias as, 714–715
alcohol use and, 718, 721, 728–729, 731–732
alexias as, 714–715, 716
amnesia as, 717–719, 729, 732, 733
anxiety disorder association with, 725, 726, 733
aphasias, 707, 708, 709–710, 714–715, 717, 726
apraxias as, 707, 715, 717, 726
autotopognosia as, 715
bacterial infections association with, 730–731
blast injuries causing, 705–706, 724–725
Broca’s aphasia as, 708, 709–710, 714, 715
areal dominance in, 709–710
circulatory system diseases association with, 709, 712–713, 714, 716, 721, 725–727, 732, 733
clinical presentation of, 707–713
communicative disorders and, 707, 708, 709–710, 714–715, 717, 726
concussions as, 705–706, 723, 724
contralateral control in, 709, 726
course and prognosis of, 732–733
degenerative and demyelinating disease association with, 727–728
delirium in, 706–707, 710, 729
diagnostic considerations for, 706–707
epidemiology of, 720–721
etiological considerations for, 723–732
fingertip agnosia as, 715
frontotemporal neurocognitive disorder as, 707, 711–712

head trauma association with, 705–706, 707, 712, 713, 720, 723–725, 732–733
HIV/AIDS infection neurocognitive disorders as, 705, 707, 713, 731
Huntington’s disease association with, 705, 707, 713, 720, 727–728, 731, 732
hypertension association with, 712–713, 721, 726–727, 732, 733
Lewy bodies disease as, 707, 712
localization theory on, 708–709, 721
major and mild neurocognitive disorders as, 706–707, 710–713
mild traumatic brain injury (mTBI) as, 705
multiple sclerosis association with, 707, 727, 731
neurosphilis association with, 730–731
overview of, 734
Parkinson’s disease association with, 707, 712, 713
perception and motility disorders and, 715–717
persistent postconcussive syndrome as, 706
phenylketonuria association with, 730
Pick’s disease association with, 727
polyneuritis association with, 728–729
prion disease neurocognitive disorders as, 707, 713, 728
pseudodementia as, 719–720
psychological and biological assessments of, 721–722
racial, ethnic and cultural factors in, 721
recent development in, 705–706
right-left disorientation as, 715
severity rating of, 706, 707
stigmatization of, 706, 711
stroke association with, 709, 712–713, 714, 716, 721, 725–726, 732, 733
substance/medication-induced neurocognitive disorder as, 707, 713, 7121
Tay-Sachs disease association with, 730, 732
toxic, infectious, and metabolic illnesses association with, 729–731
trauma- and stress-related disorder comorbidity with, 705, 725
treatments and interventions for, 729, 733
vascular neurocognitive disorder as, 707, 712–713, 726
viral infections association with, 730–731
Wernicke-Korsakoff syndrome association with, 728
Wernicke’s aphasia as, 714, 715
Neurosyphilis, 730–731
New View Task Force, 548
New York High Risk Project, 190
New York State Psychiatric Institute, 119
Nicotine use disorders. See also Substance use disorders
dual diagnosis including, 37, 40–41, 46–47, 51–52, 62–63, 77–78, 81
genetic risk factors for, 683
neurocognitive disorders and, 721
other substance use comorbidity with, 645, 683
physical illnesses impacted by, 62–63
racial, ethnic and cultural factors in, 154
secondary substance abuse models on, 77–78
Night eating syndrome, 475
Nightmare disorder, 523, 532–533, 534–535, 536, 537, 538, 541–542
Non-rapid eye movement (NREM) sleep arousal disorder, 523, 533–534, 535, 536, 537, 538, 540
Obesity:
dual diagnosis including, 63, 81
etiological considerations for, 487–488
Obsessive-compulsive anxiety disorders. See also Anxiety disorders
acceptance and commitment therapy for, 372, 373
age influences and differences in, 371–373
anxiety disorder comorbidity with, 358–359
bipolar disorder comorbidity with, 231
case studies of, 373–374
clinical features of, 356–358
cognitive-behavioral therapy for, 371–373
cognitive functioning with, 367–369
cognitive restructuring for, 372
course and prognosis of, 371–373
depression comorbidity with, 358–359
description of, 355–356
diagnostic considerations for, 358–359
dialectical behavior therapy for, 372–373
dimensional vs. categorical classification of, 7, 16
dual diagnosis including, 42, 50, 53
environmental risk factors for, 362–364, 366–367
epidemiology of, 359–360
etiological considerations for, 362–372
gender influences and differences in, 369–371
genetic risk factors for, 362–364
habit reversal training for, 372, 373
koro as culture-bound form of, 142
learning and modeling of, 366–367
life functioning with, 357
neurobiological function with, 364–366, 368–369
pharmacologic interventions for, 371, 373
psychoeducation for, 372
psychological and biological assessments of, 360–362
racial, ethnic and cultural factors in, 142, 143–144, 370–371
structured and semistructured interviews on, 120, 360–362
substance use comorbidity with, 42, 50, 53, 358
suicide/suicide ideation comorbidity with, 357, 371, 373
treatments and interventions for, 371–373
Obsessive-compulsive personality disorders: clinical picture of, 749
depressive disorder comorbidity with, 265
dimensional vs. categorical classification of, 16
dual diagnosis including, 47
epidemiology of, 749, 750
etiological considerations for, 750, 751, 752
hoarding criterion of, 360, 361 (see also Hoarding disorder)
obsessive-compulsive anxiety disorder comorbidity with, 358
psychological assessments of, 757
substance use comorbidity with, 47
symptom overlap with, 414
somatic, 451, 453, 458, 461
Panic disorder. See also Anxiety disorders
agoraphobia with, 301, 306, 314
behavioral considerations for, 323–326
biological/neurobiological function with, 319–322
bipolar disorder comorbidity with, 231
cognitive behavioral therapy for, 311, 313–314
cognitive functioning with, 326–329
depression comorbidity with, 307, 314
descriptions of, 300
diagnostic considerations for, 305, 306
dual diagnosis including, 42, 51, 53
epidemiology of, 306–307
etiological considerations for, 318–331
genetic risk factors for, 318–319, 322
personality and temperament in, 322–323
pharmacologic interventions for, 310, 313–314
self-monitoring of, 317
self-report measures for, 316
sleep panic attacks, 536, 537, 539, 540–542
structured and semistructured interviews on, 114, 315–316
substance use comorbidity with, 42, 51, 53, 307
treatments and interventions for, 310, 311, 313–314
Paranoid personality disorders: clinical picture of, 748
DSM-5 elimination of, 757, 758
epidemiology of, 749
etiological considerations for, 750, 751
Paranoid schizophrenia, 152–153, 168–169, 188
Paraphilic disorders. See Sexual dysfunctions and paraphilic disorders
Parasomnias, 532–540. See also Sleep disorders
Parkinson’s disease, 263, 707, 712, 713
Partial androgen insensitivity syndrome, 606
Passive-aggressive personality disorders, 747, 751
Personality disorders (Continued)
transference-focused therapy for, 753
trauma- and stress-related disorder comorbidity with, 51, 391
treatments and interventions for, 66, 739, 753–754, 759
Phallometry, 580–581
Phenylketonuria (PKU), 730
Physical and sexual abuse: anxiety disorders association with, 331 dissociative disorders association with, 413, 416, 417, 422, 426, 427–435 feeding and eating disorders association with, 491 obsessive-compulsive disorder association with, 367
paraphilic disorders association with, 572, 583 personality disorders association with, 751, 760 schizophrenia association with, 169–170, 185, 187 sexual dysfunction association with, 560 somatic symptom and related disorders association with, 461 trauma- and stress-related disorders association with, 387, 388, 390, 392, 394, 395, 396, 427–435 of women with dual diagnosis, 65
pharmacologic interventions for, 398
physical illnesses associated with, 63
psychological and biological assessments of, 392–393, 418
racial, ethnic and cultural factors in, 141–142, 146–147, 396–397
schizophrenia comorbidity with, 170, 185
sleep disorder comorbidity with, 388, 533, 534–535, 538
substance use comorbidity with, 42, 50, 53, 55, 60, 63, 67, 73–76, 391, 688
suicide/suicide ideation comorbidity with, 60, 390, 391
susto comparison to, 141–142
symptom overlap with, 67, 391, 400
treatments and interventions for, 397–398
Prader-Willi syndrome, 20
Pregnancy:
dual diagnosis impacting, 65
obsessive-compulsive disorder association with, 367
peripartum depressive disorders association with, 260 pseudocyesis with false belief of, 456
Premature (early) ejaculation (PE):
clinical picture of, 552
course, prognosis and treatment for, 565
description of, 549
epidemiology of, 555
etiological considerations for, 559
psychological and biological assessments of, 557
Premenstrual syndromes, 120, 143, 257
Preparedness theory, 325–326
Prion disease neurocognitive disorders, 707, 713, 728
Project E.A.T., 491
Prolonged Exposure, 397. See also Exposure therapy
Pseudocyesis, 456
Pseudodementia, 719–720
Psychoanalytic psychotherapy, 313
Psychoeducation:
for anxiety disorders, 311–312
for bipolar disorder, 226–227
for obsessive-compulsive disorders, 372
for sexual dysfunctions and paraphilic disorders, 562
for sleep disorders, 539–540
for trauma- and stress-related disorders, 397–398
Psychological debriefing interventions, 398
Psychological/psychiatric disorders. See Mental disorders
Psychopathology research. See also specific studies
clinical studies, 36, 48–54
diagnosis and assessment importance in, 69–70, 107
dual diagnosis impacting, 69–71, 81
interpretation of, 71
on personality disorders, 749–754
rational, ethnic and cultural factors in, 151–152
Research Domain Criteria (RDoC) for, 23
sample selection in, 36–37, 70–71
structured and semistructured interviews used in, 105, 107, 119
Psychoses or psychotic disorders. See also Schizophrenia
atypical, 48
cognitive functioning with, 58
depressive disorder comorbidity with, 259–260
dimensional vs. categorical classification of, 5, 6
dual diagnosis including, 45, 48, 58
gender dysphoria comorbidity with, 610, 613
rational, ethnic and cultural factors in, 152–153
structured and semistructured interviews on, 114, 117–118, 119
substance-induced psychoses, 674
substance use comorbidity with, 45, 48, 58
symptom overlap with, 67–68
Purging disorder, 475
Racial, ethnic and cultural factors:
acculturation as, 132, 133–135
age cohort of minorities impacting, 136–137
in anxiety disorders, 131, 133, 134, 136, 139–141, 142, 144, 145, 146, 304, 330
in attention deficit/hyperactivity disorder, 143
biculturalism as, 133–134
in bipolar disorder, 134, 220
clinical utility assessment for, 140–141
clinician and client interplay impacted by, 148–149
colorblindness as response to, 149
cultural acknowledgment by clinician as, 150–151
in depressive disorders, 133, 134, 137, 143, 152–153, 263, 267–268, 271, 280
diagnosis and assessment impacted by, 125–126, 132, 134, 137–147, 150–151, 152–154, 271
in dissociative disorders, 143, 412–413, 430
ethnic identity as, 132–135, 137, 146
ethnocentrism as, 138
factor pattern investigations of, 139–140
Racial, ethnic and cultural factors (Continued)
in feeding and eating disorders, 133, 134, 144, 477, 482–483, 496–497
in gender dysphoria, 625
heterogeneity of ethnic minorities as, 139
language as, 133, 138, 147
microaggression as response to, 150
mistreatment due to, 152–154
mistrust of medical institutions and establishment as, 151–152, 188
multiculturalism as, 138, 149
for Native Americans, 412, 647, 658
in neurocognitive disorders, 721, 732
in obsessive-compulsive disorders, 142, 143–144, 370–371
overview of, 131–132, 154
prevalence rates differing due to, 144
in psychoses or psychotic disorders, 152–153
racism and discrimination as, 133, 134, 136–137, 145, 146–147, 149–150, 152–153, 154
in schizophrenia, 132, 152–153, 176, 187–190
in sexual dysfunctions and paraphilic disorders, 549, 554–556, 558, 573
in sleep disorders, 539
socioeconomic status of minorities as, 132, 135–136
in somatic symptom and related disorders, 143, 144–145, 462
somatization of distress as, 144–145
spirituality and religion as, 145–146, 188
stereotyping as, 144, 149–150, 153
stigmatization as, 144–145, 150, 187, 189–190
stressful life events as, 136, 146–147 (see also Environmental risk factors)
structured and semistructured interviews on, 125–126
symptom expression impacted by, 134, 141–147
in trauma- and stress-related disorders, 141–142, 146–147, 396–397
treatments and interventions impacted by, 132, 134, 142, 147–154, 189, 220, 689
Rapid eye movement (REM) sleep behavior disorder, 523, 534, 535, 536–538, 538–539
Receiver operating characteristic analysis (ROC), 140
Relaxation training:
for anxiety disorders, 312
for dissociative disorders, 423
for sexual dysfunctions and paraphilic disorders, 566, 567
for trauma- and stress-related disorders, 398
Reliability of diagnosis and assessment, 106–107, 126
Research. See Psychopathology research
Research Domain Criteria (RDoC), 23
Restless legs syndrome, 523, 529–530, 530–531, 532
Royal Australian and New Zealand College of Psychiatrists, 497
Rumination disorder, 473
Sadism. See Sexual sadism disorder
Saliva analysis, 682
Schema-focused therapy, 753
Schizoaffective disorder, 173–174, 416
Schizoid personality disorders: clinical picture of, 748
DSM-5 elimination of, 757, 758
epidemiology of, 749
etiological considerations for, 750, 751
gender dysphoria comorbidity with, 611
Schizophrenia:
age influences and differences in, 190–191
anxiety comorbidity with, 168
behavioral family therapy for, 189
biological assessment of, 180–181
bipolar disorder comorbidity with, 173
case study of, 193–195
clinical picture of, 166–170
cognitive functioning with, 56, 57–58, 166, 177, 185–186
community functioning with, 179
coping skills training for, 184–185
costs of, 165
course and prognosis of, 190–193
delusional disorder relationship to, 174–175
depression comorbidity with, 167–168, 173, 265
description of, 166
diagnostic considerations for, 170–175
dimensional vs. categorical classification of, 4, 6–7, 14–15
dissociative disorder comorbidity with, 416
dual diagnosis including, 42, 46, 48–49, 51–52, 54, 55, 56, 57–58, 59–60, 63, 64, 67, 73, 75, 76–77, 77–78
environmental risk factors for, 179–180, 182–183, 184–185, 192
epidemiology of, 175–176
etiological considerations with, 181–190
eye tracking deficits in, 78
family assessment in, 179–180
gender dysphoria comorbidity with, 610
gender influences and differences in, 186–187, 191
genetic risk factors for, 73, 181–183
homelessness associated with, 64, 166
learning and modeling, 184–185
life functioning with, 55, 165, 166, 175–176
neurobiological function in, 76–77, 180–181, 183–184, 431
overview of, 165–166, 195–196
paranoid, 152–153, 168–169, 188
pharmacologic interventions for, 59, 167, 168–169, 180, 190–191
physical illnesses associated with, 63
posttraumatic stress disorder comorbidity with, 170, 185
psychological assessment of, 176–179
racial, ethnic and cultural factors in, 132, 152–153, 176, 187–190
schizoaffective disorder relationship to, 173–174
schizotypal personality disorder relationship to, 14–15
self-medication for, 75, 76–77, 77–78
social functioning with, 177–179, 186
social skills training for, 184–185
stigma of, 187, 189–190
structured and semistructured interviews on, 112, 117–118, 171, 177, 179
suicide/suicide ideation comorbidity with, 60, 167–168
symptom overlap with, 67–68, 171–175, 431
treatment noncompliance in, 168–169
treatments and interventions for, 59, 167, 168–169, 180, 184–185, 189, 190–191
violence and victimization of violence comorbidity with, 169–170, 185, 187
Schizotypal personality disorders:
clinical picture of, 748
dimensional vs. categorical classification of, 14–15
dual diagnosis including, 47
epidemiology of, 749
etiological considerations for, 750, 751
pharmacologic interventions for, 753
psychological assessments of, 757
substance use comorbidity with, 47
Selective mutism, 304
Self-Awareness Model, 656–657
Self-monitoring:
of anxiety disorders, 317
of somatic symptom and related disorders, 460
of substance use disorders, 649
Separation anxiety disorder, 358
Sexual dysfunctions and paraphilic disorders:
age influences and differences in, 553, 558, 583–584
anxiety comorbidity with, 559, 560, 566
autogynephilia as, 574, 608, 612, 624
biological assessments of, 556–557, 580–581
case study of, 568, 584–585
clinical picture of, 549–552, 569–575
cognitive-behavioral therapy for, 562–563, 564, 566–567, 585
cognitive functioning with, 583
course and prognosis of, 561–567, 583–584
delayed ejaculation as, 549–550, 553–556, 559–560, 565
depression comorbidity with, 549, 558–559
description of, 547–549, 569
diagnostic considerations for, 549, 553, 573–576
dissociative disorder comorbidity with, 416
dyspareunia as, 551, 560, 566
environmental risk factors for, 583
epidemiology of, 553–556, 576–579
erecile disorder as, 549, 550, 555, 556, 558–559, 563–564
etiological considerations for, 557–561, 581–583, 621
exhibitionistic disorder as, 569–570, 576, 577, 584–585
female orgasmic disorder as, 549, 550, 556, 565–566
female sexual interest/arousal disorder as, 549, 550–551, 555, 557, 558, 559, 561–563
fetishistic disorder as, 570, 576, 577
frotteuristic disorder as, 570–571, 576, 577
gender dysphoria comorbidity with, 574, 576, 605, 608, 609, 610, 612–613, 615, 624
gender dysphoria separation from, 547
genetic risk factors for, 559–560
genito-pelvic pain-penetration disorder as, 549, 551, 556, 557, 560–561, 566–567
hypersexual disorder as, 12
learning and modeling of, 582–583
male hypoactive sexual desire disorder as, 549, 551–552, 558, 561
masturbation in, 558, 560, 565–566, 569–570, 583, 584–585
mindfulness approaches for, 563, 566
neurobiological function in, 558, 559–560, 582, 621
other specified sexual dysfunctions/paraphilias as, 549, 552, 575
pedophilic disorder as, 571–572, 576, 577, 582, 583, 621
phallometric testing for, 580–581
pharmacologic interventions for, 547, 561–562, 563–564, 565, 566
physical illness comorbidity with, 63, 549, 554, 558, 560
physiotherapy for, 566–567
Sexual dysfunctions and paraphilic disorders (Continued)

polygraph testing for, 581
premature (early) ejaculation
as, 549, 552, 555, 557, 559, 565
psychoeducation for, 562
psychological and biological assessments of, 556–557, 579–581
racial, ethnic and cultural factors in, 549, 554–556, 558, 573
relaxation training for, 566, 567
sexual abuse (see Physical and sexual abuse)
sexual addictions as, 12
sexual masochism disorder as, 572–573, 575, 576, 577–578
sexual obsessions, 142, 356
sexual offenders and, 569, 570, 571, 572, 577, 578, 579–581, 583–585
sexual pain disorder as, 548, 549, 551, 556, 557, 560–561, 566–567
sexual sadism disorder as, 574, 575, 578
sleep disorders including sexual behaviors, 535, 540
substance/medication-induced sexual dysfunction as, 549, 552
systematic desensitization for, 566, 567
transvestic disorder as, 574–575, 576, 579, 608, 609, 610, 612–613, 615
treatments and interventions for, 547, 561–567, 583–584, 585
unsafe sex practices, 63
unspecified sexual dysfunctions/paraphilias as, 549, 552, 575
vaginismus as, 551, 556, 560, 566–567
vestibulectomy for, 566–567
voyeuristic disorder as, 575, 576, 578–579
Sexual masochism disorder, 572–573, 575, 576, 577–578
Sexual orientation, gender dysphoria and, 607–609, 613, 621–622, 624, 625, 626
Sexual sadism disorder, 574, 575, 578
Shenjing shuairuo, as culture-bound syndrome, 142–143
Shopping addiction, 12
Sleep disorders:
actigraphy in, 526, 530
age influences and differences in, 527, 529, 533, 534, 538, 542
anxiety comorbidity with, 527, 528, 531, 536, 537, 539, 540–542
bipolar disorder comorbidity with, 225
breathing-related sleep disorders as, 523, 529, 530, 531, 542
case study of, 540–542
circadian rhythm sleep-wake disorders as, 523, 529, 530, 531–532
cognitive-behavioral therapy for, 530
course and prognosis of, 532, 538–540
depression comorbidity with, 527, 528–529, 531
diagnostic considerations for, 528–530, 534–536
dissociative disorder comorbidity with, 416, 433–434, 435
environmental risk factors for, 531–532, 537
epidemiology of, 527, 528, 533–534
etiological considerations for, 531–532, 537–538
gender influences and differences in, 529, 534
遗传性风险因素 for, 531–532, 537–538
hypersomnolence disorder as, 523, 527, 528–530, 531, 532
inadequate/excessive sleep, 526–532
insomnia disorder as, 523, 526–527, 528–530, 531, 532, 541–542
life functioning with, 527, 528
motivational interventions for, 530
narcolepsy as, 523, 527–528, 529, 530, 531, 542
neuroscience/neurobiological function in, 524–526, 529,
531, 536, 538, 539
nightmare disorder as, 523, 532–533, 534–535, 536, 537, 538, 541–542
non-rapid eye movement (NREM) sleep arousal disorder as, 523, 533–534, 535, 536, 537, 538, 540
obesity comorbidity with, 531
overview of, 523–524, 542–543
parasomnias as, 532–540
pharmacologic interventions for, 436, 539
physical illness comorbidity with, 529, 531, 538, 539
polysomnography in, 524, 530–531, 536–537, 542
psychoeducation for, 539–540
psychological and biological assessments of, 530–531, 536–537
racial, ethnic and cultural factors in, 539
rapid eye movement (REM) sleep behavior disorder as, 523, 534, 535, 536–538, 538–539
restless legs syndrome as, 523, 529–530, 530–531, 532
sleep architecture, 525–526
sleep panic attacks as, 536, 537, 539, 540–542
sleep paralysis as, 533–536, 537, 539, 541–542
sleep stages, 525
sleep terrors as, 533–534, 535, 536, 537
sleep walking as, 533–534, 535, 536, 537
substance/medication-induced sleep disorder as, 523
trauma- and stress-related disorders comorbidity with, 388, 533, 534–535, 538
treatments and interventions for, 435, 530, 532, 538–540
types of sleep, 525
Smoking addiction. See Nicotine use disorders
Social anxiety disorder/social phobia. See also Anxiety disorders
avoidant personality disorder overlap with, 303–304
behavioral considerations for, 323–326
biological/neurobiological function with, 319–322
bipolar disorder comorbidity with, 231
cognitive-behavioral therapy for, 311–312, 313–314
cognitive functioning with, 326–329
depression comorbidity with, 309
description of, 303–304
diagnostic considerations for, 305–306
dimensional vs. categorical classification of, 15–16
dual diagnosis including, 49–50, 51, 53
epidemiology of, 308–309
etiological considerations for, 318–331
genetic risk factors for, 318–319, 322
obsessive-compulsive comorbidity with, 358–359
personality and temperament in, 323
pharmacologic interventions for, 15, 310–311, 313–314
racial, ethnic and cultural factors in, 140–141, 144, 304
selective mutism in, 304
self-monitoring of, 317
self-report measures for, 316–317
structured and semistructured interviews on, 114, 315–316
substance use comorbidity with, 49–50, 51, 53, 309
treatments and interventions for, 15, 310–311, 311–312, 313–314
Social functioning:
depressive disorders impacting, 261
feeding and eating disorders impacting, 497
personality disorders impacting, 748, 749–750 (see also Antisocial personality disorders)
role-play assessment of, 178
schizophrenia impacting, 177–179, 186
social anxiety impacting (see Social anxiety disorder/social phobia)
social skills training for, 184–185
substance use disorders impacting, 675
Social skills training, 184–185
Society for Adolescent Medicine, 497
Sociocultural factors. See also Racial, ethnic and cultural factors
age cohort as, 136–137
in dissociative disorders, 427–435
for ethnic minorities, 132, 135–137
in feeding and eating disorders, 482–483
in neurocognitive disorders, 720, 721
socioeconomic status as, 73, 132, 135–136, 176, 331, 573, 720
stressful life events as, 136 (see also Environmental risk factors)
in substance use disorders, 643, 647, 657–658
Socioeconomic status:
anxiety disorders association with lower, 331
common factors model on, 73
dual diagnosis relationship to, 73
of ethnic minorities, 132, 135–136
neurocognitive disorders association with lower, 720
paraphilic disorders associated with higher, 573
schizophrenia association with lower, 176
Somatic symptom and related disorders:
anxiety disorder comorbidity with, 458, 463
body dysmorphic disorder formerly as, 451
case study of, 463–465
clinical picture of, 452–456
cognitive-behavioral therapy for, 463
cognitive functioning with, 462
correction disorder as, 451, 454, 458, 461
costs of, 452
course and prognosis of, 463
depressive disorder comorbidity with, 261, 458, 463
description of, 451–452
diagnostic considerations for, 456–457
dimensional vs. categorical classification of, 7, 451–452
dissociation in, 409, 420
dual diagnosis including, 456–457
environmental risk factors for, 461
epidemiology of, 457–458
etiological considerations for, 460–462
factitious disorder as, 451, 455
fibromyalgia as, 461
gender influences and differences in, 458, 462
genetic risk factors for, 460
hypochondriasis as, 7, 414, 451, 458, 461, 462
illness anxiety disorder as, 451, 453–454, 458
learning and modeling of, 461
life functioning with, 452, 453
neurasthenia similarity to, 143
neurobiological function in, 461
other specified, 451, 455–456
pain disorder as, 451, 453, 458, 461
personality disorder comorbidity with, 458, 463
pseudocyesis as, 456
psychological and biological assessments of, 459–460, 464–465
psychological factors affecting other medical conditions as, 451, 454–455
rational, ethnic and cultural factors in, 143, 144–145, 462
Structured and semistructured interviews on, 113, 114, 459–460, 464–465
treatments and interventions for, 463
unspecified, 451, 456
Somatic Symptom Workgroup, 451, 456
Spiegel, Herbert, 429
Spirituality and religion: as racial, ethnic and cultural factors, 145–146, 188
religious obsessions, 356
schizophrenia and, 188
Spitzer, Robert, 22
Stanley Foundation Network study, 222
Stigmatization: dual diagnosis impacted by changes in, 43
of gender dysphoria, 611–612
of neurocognitive disorders, 706, 711
of nicotine use disorder, 63
of personality disorders, 16, 18
racial, ethnic and cultural factors in, 144–145, 150, 187, 189–190
of schizophrenia, 187, 189–190
of somatic symptom and related disorders, 456
Stress management training, 397.
See also Relaxation training
Stress-related disorders. See Trauma- and stress-related disorders
Structured and semistructured interviews:
advantages and disadvantages of, 106–111
age influences on, 109–110
Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5), 115
Anxiety Disorders Interview Schedule for DSM-IV, 111, 112, 113–115, 315–316, 360, 393
applications of, 105–111
basic issues regarding, 104–105
for bipolar disorder, 232
breath vs. depth trade-off with, 106, 110
classification system limitations on, 106, 109–110
for clinical disorders, generally, 103, 111, 112, 113–120
clinical practice use of, 105
clinical training use of, 106, 108
Cultural Formulation Interview, 125–126
Diagnostic Interview for DSM-IV Personality Disorders, 111, 112, 120–121
Diagnostic Interview Schedule for DSM-IV, 111, 112, 115–117
for differential diagnosis, 105, 111–125
for dissociative disorders, 417–418
for dual diagnosis, 36, 37, 51
for feeding and eating disorders, 478–479
International Personality Disorder Examination, 111, 113, 121–123
for obsessive-compulsive anxiety disorders, 120, 360–362
for personality disorders, 103, 105, 111, 112–113, 117, 120–125, 127, 754
for psychoses or psychotic disorders, 114, 117–118, 119
rapport hindrance through, 106, 108–109
reliability of, 106–107, 126
research-based use of, 105, 107, 119
Schedule for Affective Disorders and Schizophrenia, 111, 112, 117–118
for schizophrenia, 112, 117–118, 171, 177, 179
Structured Clinical Interview for DSM, 171
Structured Clinical Interview for DSM-5 Disorders, 120, 464–465, 679
Structured Clinical Interview for DSM-IV, 51, 236, 272–273, 393, 417, 459, 478
Structured Clinical Interview for DSM-IV Axis I Disorders, 111, 112, 118–120, 232, 315–316
Structured Clinical Interview for DSM-IV Axis II Personality Disorders, 111, 113, 123–124
Structured Clinical Interview for DSM-IV-Revised (SCID-D-R), 417
Structured Clinical Interview for DSM-IV-TR Axis I Disorders, 360, 361
Structured Clinical Interview for DSM-IV-TR Axis II Personality Disorders (SCID-II), 754
Structured Interview for Anorexic and Bulimic Disorders (SIAB-EX), 478, 479
Structured Interview for DSM-IV Personality, 111, 113, 124–125
Structured Interview for PTSD (SI-PTSD), 392
Structured Interview of Personality Organization, 756
for substance use disorders, 113, 114, 117, 119, 120, 679–681
for trauma- and stress-related disorders, 392–393
unstructured vs., 104, 111
Structured equation modeling, 139
Substance Abuse and Mental Health Services Administration, 648
Substance use disorders: age influences and differences in, 48, 647, 658, 676–677, 689–690
Subject Index

Substance use disorders (Continued)
treatments and interventions for, 642, 643, 644, 645, 646, 648, 659, 661, 677, 681, 688–689, 690–691
treatments and interventions impacted by, 58–59, 60–62, 65–66
violence associated with, 59–60, 646, 660
withdrawal symptoms with, 645–646, 673, 674, 675
Suicide and suicide ideation:
- anxiety disorder comorbidity with, 306
- bipolar disorder comorbidity with, 60, 220, 221, 236
- body dysmorphic disorder comorbidity with, 357, 371, 373
depressive disorder comorbidity with, 60, 253
- dissociative disorder comorbidity with, 416, 435
dual diagnosis impacting, 59–60
- gender dysphoria comorbidity with, 617, 619, 626
- obsessive-compulsive disorder comorbidity with, 357, 371, 373
- personality disorder comorbidity with, 739, 748
- schizophrenia comorbidity with, 60, 167–168
- substance use comorbidity with, 47, 56, 59–60
- trauma- and stress-related disorders comorbidity with, 60, 390, 391
Susto, as culture-bound syndrome, 141–142
Sybil (Sybil book/movie), 417, 429
Systematic desensitization, 566, 567
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 220, 227
Taijin Kyofusho, as culturally bound syndrome, 304, 330
Tay-Sachs disease, 730, 732
Temperament. See Personality and temperament

Theories:
- bidirectional models as, 79–80
- common factors models as, 72–74
- of dual diagnosis, 71–80
- item response theory (IRT) methodology, 13–14, 39–40
- localization theory, 708–709, 721
- preparedness theory, 325–326
- secondary psychiatric disorder models as, 78–79
- secondary substance abuse models as, 74–78
- Thiamine treatments, 729
- Tobacco addiction. See Nicotine use disorders
- Training. See Coping skills training; Habit reversal training; Psychoeducation; Relaxation training; Social skills training; Stress management training
- Transference-focused therapy, 753
- Transsexualism:
  - case study of, 625–627
  - clinical picture of, 605–609
  - cognitive functioning with, 624
  - course and prognosis of, 614–616
  - description of, 603–605
  - diagnostic considerations for, 609–612
  - environmental risk factors for, 620, 623–624
  - epidemiology of, 612–613
  - etiological considerations for, 619–625
  - gender influences and differences in, 606, 607–609, 612, 624–625
  - genetic risk factors for, 619–621
  - history and terminology of, 603–605
  - hormone therapy for, 610, 612, 615, 616–617, 621, 624–625, 626
  - learning and modeling of, 623–624
  - neurobiological function in, 621–623
  - psychological and biological assessments of, 613–614
  - racial, ethnic and cultural factors in, 625
  - sex reassignment for, 603, 605, 608–609, 612, 614, 615–616, 618–619, 625
  - treatments and interventions for, 603, 605, 608–609, 610, 612, 614, 615–619, 621, 624–625, 626
- Transtheoretical model (TTM), 677
- Transvestic disorder:
  - clinical picture of, 574–575
  - diagnostic considerations for, 576
  - epidemiology of, 579
  - gender dysphoria association with, 574, 576, 608, 609, 610, 612–613, 615
- Trauma- and stress-related disorders:
  - adjustment disorders as, 387, 389, 390–391, 392, 393, 395, 396–400, 611
  - anxiety comorbidity with, 391
  - bipolar disorder comorbidity with, 231
  - case studies of, 399–400
  - clinical features of, 390–391
  - cognitive-behavioral therapy for, 396, 397–398
  - cognitive functioning with, 388, 396
  - cognitive restructuring for, 396, 397–398
  - course and prognosis of, 397–398
  - environmental risk factors for, 396–397
  - diagnostic considerations for, 391, 399, 400
  - dimensional vs. categorical classification of, 7, 390
  - dissociation, posttraumatic model of, 407, 408, 409, 416, 418, 427–435
  - dual diagnosis including, 42, 50, 51, 53, 55, 60, 63, 67, 75–76
  - environmental risk factors for, 394, 395–396
  - epidemiology of, 391–392
  - etiological considerations for, 393–397
  - exposure therapy for, 397–398
feeding and eating disorder comorbidity with, 493, 500–501
gender dysphoria comorbidity with, 611
gender influences and differences in, 396
genetic risk factors for, 393–394
learning and modeling of, 395–396
neurobiological function in, 394–395, 685–686
neurocognitive disorder comorbidity with, 705, 725
personality and temperament in, 322–323
personality disorder comorbidity with, 51, 391
pharmacologic interventions for, 398
physical illnesses associated with, 63
psychoeducation for, 397–398
psychological and biological assessments of, 392–393, 418
psychological debriefing interventions for, 398
racial, ethnic and cultural factors in, 141–142, 146–147, 396–397
relaxation training for, 398
schizophrenia comorbidity with, 170, 185
sleep disorder comorbidity with, 388, 533, 534–535, 538
stress management training for, 397
structured and semistructured interviews on, 392–393
substance use comorbidity with, 42, 50, 53, 55, 60, 63, 67, 75–76, 391, 656, 685–686, 688
suicide/suicide ideation comorbidity with, 60, 390, 391
symptom overlap with, 67, 391, 400, 414
treatments and interventions for, 397–398

Treatments and interventions: acceptance and commitment therapy as, 312, 372, 373
for anxiety disorders, 15, 310–315
behavioral family therapy as, 189
for bipolar disorder, 59, 220, 225–226, 236, 237–238
clinician and client interplay in, 148–149
562–563, 564, 566–567, 585
cognitive restructuring as, 311–312, 372, 396, 397–398, 423
coping skills training as, 184–185, 423, 493, 677, 681
for depressive disorders, 11, 60–61, 253, 262, 282
diagnosis as foundation for, 22–23, 107, 648, 677
dialectical behavior therapy as, 372–373, 423, 493, 753
for dissociative disorders, 423, 434–435
EROS Clitoral Therapy Device as, 563, 566
exposure therapy as, 142, 311–312, 314, 371–372, 397–398
eye movement desensitization and reprocessing as, 313
family-focused therapy as, 226, 227, 228, 497–498
for feeding and eating disorders, 493, 497–499
for gender dysphoria, 603, 605, 608–609, 610, 612, 614, 615–619, 621, 624–625, 626
Guided Self-Change as, 659
habit reversal training as, 372, 373
hormone therapy as, 610, 612, 615, 616–617, 621, 624–625, 626
insurance coverage for, 16
interpersonal and social rhythm therapy as, 226, 227
interpersonal therapy as, 226, 227, 313, 498, 499
meditation as, 312
menthalization-based therapy as, 753
mindfulness approaches to, 312–313, 423, 563, 566
motivational interventions as, 530, 644, 648, 659, 661
for neurocognitive disorders, 729, 733
noncompliance with, 58–59, 153, 168–169, 226, 690
for obsessive-compulsive disorders, 371–373
for personality disorders, 66, 739, 753–754, 759
pharmacologic (see Pharmacologic interventions)
physiotherapy as, 566–567
positive psychology as, 262
psychoanalytic psychotherapy as, 313
psychological debriefing interventions as, 398
racial, ethnic and cultural factors impacting, 132, 134, 142, 147–154, 189, 220, 689
relaxation training as, 312, 398, 423, 566, 567
schema-focused therapy as, 753
for schizophrenia, 59, 167, 168–169, 180, 184–185, 189, 190–191
service utilization of, 60–62, 132, 134, 189, 688–689
sex reassignment as, 603, 605, 608–609, 612, 614, 615–616, 618–619, 625
for sexual dysfunctions and paraphilic disorders, 547, 561–567, 583–584, 585
for sleep disorders, 436, 530, 532, 538–540
social skills training as, 184–185
for somatic symptom and related disorders, 463
stress management training as, 397
Tuberous sclerosis, 20

Turner’s syndrome, 606

Tuskegee Study of Untreated Syphilis in the African American Male, 151–152

Uniting Couples (in the treatment of) Anorexia Nervosa (UCAN), 498

Urinalyses, 652–653, 681–682

Vacuum construction devices (VCD), 564

Vaginismus, 551, 560, 566, 567


Vascular neurocognitive disorder, 707, 712–713, 726

Vestibulectomy, 566–567

Violence. See also Anger and hostility
dual diagnosis association with, 59–60
paraphilic disorders involving, 569, 572–584
physical and sexual abuse (see Physical and sexual abuse)
racial, ethnic and cultural factors in, 153
schizophrenia and, 169–170, 185, 187
self- (see Suicide and suicide ideation)
sleep disorders and, 539, 540
substance use associated with, 59–60, 646, 660
trauma disorders associated with (see Trauma- and stress-related disorders)
von Recklinghausen’s disease, 20
Voyeuristic disorder, 575, 576, 578–579

Weight issues. See Feeding and eating disorders; Obesity

Wellcome Trust Case Control Consortium 3, 484

Wernicke-Korsakoff syndrome, 728

Wernicke’s aphasia, 714, 715

White, William Alanson, 746

Wilbur, Cornelia, 429

Women. See also Gender influences and differences
amenorrhea in, 474
dual diagnosis issues for, 64–65

female orgasmic disorder in, 549, 550, 556, 560, 565–566
female sexual interest/arousal disorder in, 549, 550–551, 555, 557, 558, 559, 561–563
gender dysphoria in, 547, 574, 576, 603–627
genito-pelvic pain-penetration disorder in, 549, 551, 556, 557, 560–561, 566–567
paraphilic disorders in, 570, 571, 572, 573, 574, 577, 578–579
physical and sexual abuse of, 65, 170, 187 (see also Physical and sexual abuse)
pregnancy among, 65, 260, 367, 456
premenstrual syndromes in, 120, 143, 257
substance use among, specifically, 64–65, 657–658, 688

World Health Organization (WHO):
bipolar disorder epidemiological study by, 219
Composite International Diagnostic Interview (CIDI), 10, 47, 116, 273, 459, 478, 679

ICD by (see International Classification of Diseases)
Joint Program for the Diagnosis and Classification of Mental Disorders, 121
Mental Health Epidemiologic Survey, 392, 476

normal weight guidelines of, 474

schizophrenia epidemiological study by, 175

substance use epidemiological statistics by, 646

Well-Being Index (WHO-5), 271–272

World Mental Health Surveys (WMHS), 47, 457

World Professional Association for Transgender Health (WPATH), 604, 616

Yale Family Study of Comorbidity of Substance Disorders, 73

Treatments and interventions (Continued)


systematic desensitization as, 566, 567

Systematic Treatment Enhancement Program for Bipolar Disorder as, 220, 227

thiamine treatments as, 729

transference-focused therapy as, 753

for trauma- and stress-related disorders, 397–398

Uniting Couples (in the treatment of) Anorexia Nervosa (UCAN), 498

vacuum construction devices as, 564

vestibulectomy as, 566

Trichotillomania (TTM):
case study of, 374

course and prognosis of, 372–373
description of, 356
diagnostic considerations for, 359

evironmental risk factors for, 363, 367

epidemiology of, 360

etiological considerations for, 363, 366, 367, 371

gender influences and differences in, 371

genetic risk factors for, 363

neurobiological function with, 366


psychological and biological assessments of, 361

racial, ethnic and cultural factors in, 371

structured and semistructured interviews on, 120

treatments and interventions for, 372–373

Trisomy 21, 20, 720

Tuberous sclerosis, 20